

Europäisches Patentamt European Patent Office Office européen des brevets

(11) **EP 1 731 032 A1**

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication: 13.12.2006 Bulletin 2006/50

(21) Application number: 05727975.4

(22) Date of filing: 31.03.2005

(51) Int Cl.: A01K 67/027^(2006.01) C07K 16/18^(2006.01) C12N 15/09^(2006.01)

(86) International application number: PCT/JP2005/006298

(87) International publication number: WO 2005/094572 (13.10.2005 Gazette 2005/41)

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: 31.03.2004 JP 2004107669

(71) Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA Tokyo, 115-8543 (JP)

(72) Inventors:

 KODAMA, Tatsuhiko 1540002 (JP)

YAMADA, Yoshiki,
 CHUGAI SEIYAKU KABUSHIKI KAISHA
 Gotenba-shi,
 Shizuoka 4120038 (JP)

 KAMADA, Nobuo, CHUGAI SEIYAKU KABUSHIKI KAISHA Gotenba-shi, Shizuoka 4120038 (JP)

 JISHAGE, Kou-ichi, CHUGAI SEIYAKU KABUSHIKI KAISHA Gotenba-shi, Shizuoka 4120038 (JP)

(74) Representative: Vossius & PartnerSiebertstrasse 481675 München (DE)

(54) NONHUMAN ANIMALS FOR ANTIBODY PRODUCTION, AND METHODS AND SYSTEMS FOR PRODUCING ANTIBODIES USING SUCH ANIMALS

(57) Membrane proteins that are background antigens were solubilized, and transgenic animals were produced using genes encoding these soluble proteins. Antibodies against the background antigen membrane proteins comprised in the immunogens were not found in these transgenic animals, and even when genes encoding soluble proteins were used, immunotolerance against the full-length membrane proteins could be induced.

Moreover, by expressing the background antigen membrane proteins as soluble proteins inside the bodies of transgenic animals, unfavorable phenotypes that appear when the full-length membrane proteins are expressed could be avoided, and such animals were made widely available as immunized animals.

Description

Technical Field

[0001] The present invention relates to systems and such for antibody production in which animals are immunized with immunogens comprising, other than target antigens, background antigens to produce antibodies specific to the target antigens, and particularly relates to systems and such in which immunized animals carry genes encoding soluble forms of membrane proteins so that immunotolerance against the background antigens comprising the membrane proteins is induced in the immunized animals.

Background Art

10

30

35

40

55

[0002] Antibody production is very difficult when it is difficult to express and purify the target antigens necessary to produce the antibodies. This tendency is pronounced for membrane proteins. Therefore, a technique has been developed which uses proteins that are difficult to express or purify, such as seven-transmembrane proteins, as antigens by expressing the antigenic proteins on the membrane surface of the *Autographa californica* nuclear polyhedrosis virus (AcNPV), which belongs to *Baculovirus* (Non-Patent Document 1).

[0003] However, although baculovirus expression systems are useful as expression systems for various proteins comprising membrane proteins, there are many gp64 membrane proteins (Non-Patent Documents 2 and 3) on the surface of baculoviruses, and these contaminate the expression products obtained from baculovirus expression systems. gp64 is a 64-kDa protein, a major component of the surface of budding viruses, and known to be a protein involved in envelope fusion at low pH. This gp64 is more easily recognized as non-self than human-derived antigenic proteins, and when gp64 contaminates immunogens, antibodies are produced more readily against gp64 than against the target antigens. Therefore, when preparing immunogens using a baculovirus expression system, it is difficult to produce and obtain specific antibodies against antigenic proteins (Non-Patent Document 4). As a means to solve this problem, the present inventors generated gp64 transgenic mice (hereinafter referred to as "Tgm"). Before their immune system develops, these Tgm (hereinafter referred to as "gp64Tgm") carry an exogenous gp64 in the same way as the endogenous genes. Therefore, these Tgm show immunotolerance against gp64, just as they do for the endogenous genes. Thus they recognize target antigenic proteins expressed using baculovirus, enabling the advantageous production of specific antibodies (Patent Document 1).

[0004] However, the gp64Tgm showed a phenotype with no testes development nor sperm formation. Therefore, the maintenance of the strain was restricted to females, and although the strain could be maintained, efficient breeding was not possible. In addition, there were some difficulties when producing crossbred animals by crossing with other knockout mice or Tgm. [Patent Document 1] WO 03/104453.

[Non-Patent Document 1] Biotechnology, vol.13, 1079-84, 1995.

[Non-Patent Document 2] Journal of Immunological Methods, vol.234, 123-135, 2000.

[Non-Patent Document 3] Journal of Virology, vol.70, No.7, 4607-4616, 1996.

[Non-Patent Document 4] Journal of Virology, vol.69, No.4, 2583-2595, 1995.

Disclosure of the Invention

Problems to be Solved by the Invention

[0005] As described above, the aforementioned gp64Tgm are useful as animals to be immunized for producing specific antibodies against proteins expressed using baculoviruses, but gp64Tgm had a problem of being infertile. Therefore, an objective of the present invention is to generate even more useful Tgm without unfavorable phenotypes such as inhibited testes development, and to provide methods and such for producing antibodies using these novel Tgm, so that the expression and maintenance of such exogenous membrane proteins in transgenic animals are enabled.

Means to Solve the Problems

[0006] The present inventors predicted that the inhibition of testes development is caused by gp64 expression on cell membranes in the testes. Soluble gp64 (hereinafter referred to as "sgp64"), produced by deleting the transmembrane region from (full-length) gp64, was linked to the pCAGGS vector (Gene, vol. 108, 193-200,1991) to construct an sgp64 expression vector (hereinafter referred to as "pCAG-sgp64 vector"). When sgp64Tgm were produced by introducing this vector into mice, male Tgm maintained their fertility, and the present inventors successfully overcame the conventional problem of inhibited testes development. These sgp64Tgm and control non-transgenic mice were immunized using a

budding baculovirus, sera were collected, and the presence of immunotolerance against gp64 was examined. As a result, antibodies against gp64 were produced in control non-transgenic mice, but were hardly detected in sgp64Tgm. In other words, the present inventors were able to avoid the male infertility observed in conventional gp64Tgm by using sgp64, and were able to establish transgenic mice effective for producing antibodies using antigens expressed in baculovirus. The present invention is based on these findings, and more specifically, relates to the following:

- (1) a nonhuman animal carrying a gene encoding a soluble form of a membrane protein;
- (2) the nonhuman animal of (1), which is a transgenic animal into which a gene encoding a soluble protein (also referred to as "soluble form protein" in the present application) has been introduced exogenously;
- (3) the nonhuman animal of (2), which is a progeny of the transgenic animal into which a gene encoding a soluble protein has been introduced exogenously;
- (4) the nonhuman animal of any one of (1) to (3), wherein the membrane protein is derived from a virus;
- (5) the nonhuman animal of (4), wherein the virus is a baculovirus;
- (6) the nonhuman animal of (5), wherein the membrane protein is gp64;
- (7) the nonhuman animal of (6), wherein the soluble protein is gp64 that lacks a transmembrane region;
- (8) the nonhuman animal of (6), wherein the soluble protein comprises an extracellular region of gp64;
- (9) the nonhuman animal of any one of (1) to (8), wherein the nonhuman animal is a mouse;
- (10) the nonhuman animal of any one of (6) to (9), wherein the male is fertile;
- (11) a method for producing an antibody, which comprises the steps of:

immunizing the nonhuman animal of any one of (1) to (10) with an immunogen comprising a target antigen; and obtaining an antibody against the target antigen or a gene encoding such an antibody;

- (12) the method of (11) for producing an antibody, wherein the immunogen is a viral particle or a portion thereof;
- (13) the method of (12) for producing an antibody, wherein the virus is a baculovirus;
- (14) the method of any one of (11) to (13) for producing an antibody, wherein the target antigen is a membrane protein; and
- (15) a system for producing an antibody, which comprises the nonhuman animal of any one of (1) to (10).
- 30 [0007] To facilitate the understanding of the present invention, the meaning of some of the presupposed terms are explained.
 - **[0008]** In the present invention, the term "target antigen" denotes antigens recognized by subject antibodies. The target antigens can be selected from any substance having antigenicity. Specifically, proteins, sugar chains, lipids, inorganic substances, or such are known as substances showing antigenicity. The target antigens may be naturally occurring or artificially synthesized. The artificially synthesized target antigens comprise recombinant proteins prepared by genetic engineering technology, and many kinds of chemically-synthesized organic compounds.
 - [0009] The term "background antigen" denotes substances comprising antigenic determinants for which antibody generation is not desired, or denotes the antigenic determinants themselves. For example, any antigenic substance that is not a target antigen, but which contaminates the target antigen, is a background antigen. Typical background antigens are proteins contaminated within crudely purified target antigens. More specifically, host cell-derived proteins in a recombinant protein are examples of background antigens. The term "background antigen" may also be defined to mean antigens that are comprised within an immunogen for inducing subject antibody generation, and that induce production of a non-subject antibody. Generally, a background antigen is thought to indicate an antigenic substance other than a target antigen. In the present invention, however, antigenic determinants present on target antigen molecules may also be comprised in the background antigens. For example, if an antigenic determinant for which antibody generation is undesired is present on a target antigen molecule, the antigenic determinant is comprised in the background antigens of the present invention.
 - [0010] The term "immunotolerance" denotes a condition in which an immune response, specific to an antigen that is an immunotolerance target (an immunotolerance antigen), is lost or decreased. When the level of a subject's immune response to an immunotolerance antigen is reduced compared to that of a normal immunized animal, the subject can be regarded to comprise immunotolerance against the immunotolerance antigen. For example, when the amount of an antibody generated against an immunotolerance antigen is decreased in response to the administration of an immunotolerance antigen, the level of immune response is then considered to be low.

55 Brief Description of the Drawings

[0011]

10

15

20

25

35

40

45

50

Fig. 1-a shows the nucleotide sequence of the soluble gp64 gene used in the Examples. Nucleotides 1 to 720 are shown.

Fig. 1-b shows the nucleotide sequence of the soluble gp64 gene used in the Examples. Nucleotides 721 to 1486 are shown.

Fig. 2 shows a schematic map of the pCAG-sgp64 vector.

Fig. 3 is a photograph showing a Western blot with anti-mouse IgG to confirm that immunotolerance against gp64 is induced in sgp64Tgm.

Best Mode for Carrying Out the Invention

5

10

30

35

40

45

50

55

[0012] The present invention provides transgenic animals useful for producing antibodies against target antigens when using immunogens that have, other than the target antigens, membrane proteins contaminating as background antigens, and also provides methods and systems for antibody production using such transgenic animals.

[0013] As described above, in the present invention, the background antigens are membrane proteins. Examples of cases where membrane proteins contaminate as background antigens comprise the contamination of membrane proteins derived from host organisms used to prepare target antigens, and the contamination of membrane proteins derived from viruses used for the expression systems. For example, when the target antigen is expressed together with viral vectorderived membrane proteins, such as the case in which a baculovirus expression system is used to prepare a membrane protein as a target antigen, large quantities of vector-derived membrane proteins contaminate as background antigens. [0014] Herein, "membrane protein" ordinarily means a protein that constitutes a biological membrane, and for example, it refers to a protein embedded in a biological membrane; however, in the present invention, it also comprises proteins linked to a cell membrane surface via an anchor and the like, such as GPI-anchored proteins. Moreover, virus-derived membrane proteins ordinarily refer to proteins that constitute the envelope of budding viruses. For example, in baculoviruses, a protein called gp64 corresponds to a membrane protein. The structure of many of these membrane proteins comprises a region embedded in the cell membrane (transmembrane region), a region exposed on the outer side of the cell membrane (extracellular region), and a region positioned on the inner side of the cell membrane (intracellular region). Functionally, membrane proteins comprise proteins constituting membranes, receptors, proteins involved in signal transduction and the like such as transporters, and proteins such as membrane enzymes that perform specific reactions. Therefore, when such an exogenous membrane protein is introduced into an animal to be immunized, its expression in any biological membrane of the animal to be immunized will not only induce immunotolerance, but may also confer other unfavorable characteristics. For example, the problem of male infertility arises in mice into which the baculovirus-derived membrane protein gp64 has been introduced.

[0015] In the nonhuman animals of the systems for antibody production of the present invention, immunotolerance is induced against virus-derived membrane proteins that may be contaminating immunogens as the aforementioned background antigens. For example, nonhuman animals in which immunotolerance against baculovirus-derived membrane protein gp64 has been induced are used as the immunized animals when using immunogens prepared with the baculovirus expression systems. In the past, methods where immunized animals carry a gene encoding a full-length membrane protein, which is a background antigen, had been developed as methods for inducing immunotolerance; however, in the present invention, nonhuman animals carry a gene encoding a solubilized membrane protein (hereinafter referred to as a "soluble protein").

[0016] A "soluble protein" (also referred to as "soluble form protein" in the present application) refers to a membrane protein originally expressed on a biological membrane (insoluble protein) that has been modified so that it may be expressed outside a biological membrane. As described above, since membrane proteins comprise those that function as receptors or transporters that may be involved in signal transduction and those that function as switches in the living body, such as membrane enzymes, when such membrane proteins are expressed in the biological membranes of the animals to be immunized, they not only induce immunotolerance against background antigens in the animals to be immunized but can also confer unfavorable characteristics to the animals. To avoid such inconveniences, in the present invention, the membrane proteins are converted to soluble forms so that they may be expressed outside biological membranes. In addition, compared to conventional methods that use full-length membrane proteins and express them on biological membranes, which are localized sites, the present invention allows membrane proteins to be expressed systemically in the cytoplasm in their soluble form; therefore, the efficiency of immunotolerance induction is expected to improve.

[0017] In the present invention, genetic engineering methods for modifying genes encoding membrane proteins are used to modify the membrane proteins into soluble forms. An example of a genetic engineering method for solubilizing membrane proteins is the deletion of a transmembrane region. The degree of transmembrane region deletion may be deletion of a portion of the transmembrane region, or deletion of the entire transmembrane region, so long as the membrane protein can be expressed extracellularly. Since transmembrane regions generally form an α -helical structure comprising 20 to 30 amino acids, proteins can also be solubilized by introducing mutations to change this structure.

[0018] As regions other than the transmembrane region, there are the intracellular region and the extracellular region; however, when modifying membrane proteins into soluble proteins, the intracellular region is not necessary, and soluble proteins may be limited to the extracellular region alone, which is equipped with antigenic determinants that can induce immunotolerance. Moreover, the extracellular region may also be limited to regions that may induce immunotolerance, such as regions that maintain antigenicity and are equipped with antigenic determinants capable of inducing immunotolerance against membrane proteins.

[0019] In addition to deleting the transmembrane region and such from membrane proteins and such, the aforementioned soluble proteins may comprise a chimeric protein into which other peptides and such have been added or inserted. The peptides added/inserted to the chimeric proteins may be antigenic determinants of other background antigens (these "other background antigens" may or may not be membrane proteins). Thus, immunotolerance against multiple background antigens can be induced by equipping a single protein with antigenic determinants against multiple background antigens.

[0020] As an example of the construction of a soluble protein, the case of baculovirus membrane protein gp64 will be used and explained. gp64 is encoded by the DNA sequence of SEQ I17 NO: 1; its transmembrane region is encoded by nucleotides 1465 to 1515, and its extracellular region is encoded by nucleotides 1 to 1464. Therefore, to solubilize gp64, the aforementioned transmembrane region can be deleted, the sequence encoding the amino acids responsible for the α -helix structure can be substituted with that of other amino acids, or so forth. Also, the entire protein, comprising 488 amino acid residues that are encoded by nucleotides 1 to 1464 shown in SEQ ID NO: 3, may be used for the aforementioned extracellular region, or the length of the extracellular region can be shortened to within a range that can maintain cross-reactivity with gp64 and induce immunotolerance against gp64. Furthermore, one or more modifications such as amino acid deletion, substitution, addition, or insertion can be made to the amino acid sequence of the extracellular region of gp64 (amino acid residues 1 to 488 in the amino acid sequences of SEQ ID NOs: 1 to 3), within a range that allows the induction of immunotolerance against gp64 in the immunized animals described below.

20

30

35

40

45

50

[0021] In the present invention, immunotolerance is induced by making nonhuman animals carry genes encoding such soluble proteins. Nonhuman animals that can be used in the present invention comprise, for example, monkeys, pigs, dogs, rats, mice, and rabbits. For example, rodents such as rats, mice, and hamsters are preferable as nonhuman animals. To induce immunotolerance by preparing transgenic animals, it is advantageous to use nonhuman animals which mature fast and for which gene manipulation technologies have been established, such as rodents. Mice in particular are nonhuman animals that meet these requirements at a high level.

[0022] Nonhuman animals carrying a gene encoding the aforementioned soluble protein can be obtained by producing transgenic animals into which a gene encoding the soluble protein has been introduced as an exogenous gene. For example, transgenic mice can be produced according to known methods (Proc. Natl. Acad. Sci. USA 77: 7380-7384 (1980)). Specifically, subject genes are introduced into mammalian totipotent cells, and then the cells are brought up into individuals. A subject transgenic mouse can be obtained from the individuals thus obtained by screening for individuals in which the introduced gene has been integrated into both somatic cells and germ cells. Fertilized eggs, early embryos, and cultured cells with multipotency such as ES cells, and such, can be used as the totipotent cells for introducing a gene. More specifically, they can be produced by the method in the Examples described below.

[0023] The nonhuman animals carrying a gene encoding a soluble protein of the present invention may be offspring of the above-mentioned transgenic animals. Once transgenic animals are established, transmission to the offspring of the characteristics (in the present invention, the characteristic of immunotolerance) caused by the introduced gene is usually easy. However, since the previously developed transgenic animals into which baculovirus gp64 has been introduced had developed the problem of male infertility, it was difficult to efficiently reflect the characteristic of immunotolerance in their offspring. On the other hand, in the present invention, by producing transgenic animals using genes encoding soluble forms of the membrane proteins, the expression of unfavorable characteristics found in the transgenic animals into which genes encoding full-length membrane proteins have been introduced was avoided. As one example, the use of a gene encoding a soluble form of the baculovirus gp64 protein in the production of transgenic animals has made it simple to transmit characteristics to the offspring by maintaining male fertility and efficient reproduction. Since transgenic animals carrying soluble gp64 can reproduce efficiently, and their offspring also carry the characteristic of immunotolerance, they become useful as animals to be immunized for antibody production and such, as described below. Therefore, by making nonhuman animals carry a gene encoding a soluble protein rather than a full-length membrane protein, immunized animals in which immunotolerance has been induced against that membrane protein can be more widely and easily used.

[0024] Nonhuman animals carrying a gene encoding a soluble form of a membrane protein of the present invention can be produced based on gene deficient animals in which the target antigenic protein is deleted (so-called knockout animals). Nonhuman animals carrying a gene encoding the soluble form of the membrane protein may also be produced by crossing background antigen-expressing transgenic animals with such target antigenic protein knockout animals. This enables the characteristics of background antigen expression and target antigenic protein deletion to be conferred to the nonhuman animals. In such animals carrying both characteristics, immunotolerance against background antigens

is induced, while the target antigen is more readily recognized as a foreign substance since the animals do not innately carry the target antigen; therefore, the desired antibodies can be obtained efficiently.

[0025] In the nonhuman animals of the present invention, in which immunotolerance against background antigens is induced, suppression of antibody production against all background antigens that may be comprised in an immunogen is not necessarily important. Production of antibodies that recognize background antigens is tolerated if it is within a range that does not interfere with production and collection of antibodies against the target antigen. Therefore, for example, even animals to be immunized in which immunotolerance has been induced against only the major background antigens may be utilized as favorable immunized animals of the present invention.

[0026] The present invention relates to methods for producing antibodies by utilizing nonhuman animals that carry genes encoding the abovementioned soluble forms of membrane proteins.

[0027] These methods comprise the step of immunizing nonhuman animals carrying a gene encoding the abovementioned soluble form of a membrane protein with an immunogen comprising, other than a target antigen, this membrane protein as a background antigen, and the step of obtaining antibodies against the previously-described target antigen or genes encoding these antibodies.

[0028] The immunogens of the present invention comprise, other than a target antigen, at least a membrane protein as a background antigen. Generally, a target antigen comprises substances derived from biological materials. Biological materials are complex mixtures comprising various components. Thus, target antigens are usually prepared using various mixtures as starting materials. Therefore, it is difficult to obtain highly-purified target antigens. In other words, it involves a lot of time and effort to isolate a large quantity of a highly pure target antigen. The present invention provides methods that enable efficient acquisition of antibodies against target antigens using such immunogens which have, other than a target antigen, membrane proteins contaminating as background antigens.

[0029] More specifically, examples of the immunogens of the present invention comprise cells, cell culture solutions, cell lysates, viruses, and crude antigens, in which membrane proteins may be contaminating as background antigens. When using cells or viruses, a gene encoding a desired antigen can be introduced into the cells or viruses by gene recombination techniques, and those that artificially express the desired antigen can be used. Whole cells or viruses as well as portions thereof can be used as the immunogens. Furthermore, just cell membrane or viral envelope portions may be used as the immunogens. When such whole cells or viruses, or portions thereof, such as their cell membrane or viral envelope, are used as the immunogen, membrane proteins comprised in the cell membrane or viral envelope contaminate as background antigens.

[0030] One preferable immunogen of the present invention is a viral particle or portion thereof. Viruses are comprised of relatively simple components, including nucleic acids, and limited proteins, saccharides, and such. Consequently, the types of background antigens that may interfere with target antigen acquisition are also limited. Background antigens from viral particles or portions thereof that interfere with the acquisition of target antigen comprise membrane proteins on the surface of the particles. When administered to the animals to be immunized, the particle surfaces are highly antigenic, and can readily induce antibody production. Therefore, the methods for producing antibodies based on the present invention can be carried out more favorably if, even from among these few background antigens, immunotolerance in the animals to be immunized is induced against background antigens that are membrane proteins on the particle surface and the like.

30

35

40

45

50

55

[0031] In the present invention, baculovirus is one among the preferred among the viruses that can be used as immunogens. Baculoviruses are insect viruses that comprise a structure whereby a double-stranded DNA genome is covered with a capsid protein. Expression systems using Nucleopolyhedrovirus (NPV), a type of baculovirus, are useful as systems for expressing exogenous genes. NPV comprises strong promoter activity. Therefore, any protein can be produced in large quantities by inserting an exogenous gene into the NPV genome. Specifically, strong expression of any exogenous gene is induced by recombinantly substituting the gene coding for the protein called polyhedron with the exogenous gene.

[0032] The foreign genes that are expressed in the aforementioned baculovirus expression systems are not particularly limited, and any gene may be used; however, since baculoviruses can be utilized as systems suitable for expressing membrane proteins, an example of a suitable gene is a gene encoding a membrane protein. In the baculovirus expression systems, a subject membrane protein can be expressed along with a baculovirus envelope protein in a form that retains its structure. Another advantage of the baculovirus expression systems is that the expression products can be easily recovered as budding viral particles.

[0033] As methods for expressing membrane proteins which are the target antigens using baculoviruses, for example, the method using budding baculoviruses described in WO 98/46777 and Loisel *et al.* (Loisel, T.P. et al., Nature Biotech. 15: 1300-1304 (1997)) can be used. More specifically, a recombinant vector for insect cells comprising a gene encoding an exogenous protein is constructed, and introduced, along with baculoviral DNA, into insect cells such as Sf9. The exogenous membrane protein encoded by the recombinant vector is expressed on mature viral particles (virions), which are released by infected cells to the outside of cells prior to infected cell death. Recombinant viruses that express the exogenous protein can thus be obtained.

[0034] In the present invention, a budding virus is a virus that is released from infected cells by budding. Generally, viruses covered with an envelope can bud from cells infected with these viruses, and are released continuously, even when the cells have not been destroyed. On the other hand, adenoviruses that are not covered by an envelope, and herpes viruses that are covered by a nuclear envelope, are released from the cells all at once, upon cell destruction. Budding viruses are particularly preferable in the present invention. In addition, those skilled in the art can suitably select hosts to be infected with a recombinant virus, depending on the type of virus used, so long as viral replication is possible in the host. For example, insect cells such as Sf9 cells can be used when using baculoviruses. Generally, protein expression systems using baculoviruses and insect cells are considered to be useful systems because modifications that occur at the same time as translation or post-translationally, such as fatty acid acetylation or glycosylation, are carried out in the same way as with mammalian cells and because the expression level of heterologous proteins in such systems is greater than that in mammalian cell systems (Luckow V.A. and Summers M.D., Virol. 167: 56 (1988)).

[0035] The viruses expressing exogenous proteins, which are the target antigens, can be obtained by, for example, culturing a host that has been infected with a recombinant virus comprising a gene that encodes an exogenous protein. Alternatively, using methods such as the above-mentioned methods of W0 98/46777 and *Loisel et al* (Loisel, T.P. et al., Nature Biotech. 15: 1300-1304 (1997)), a recombinant vector encoding an exogenous protein can be introduced into an insect cell along with a baculovirus, and exogenous proteins can be expressed on the envelope of the baculovirus released outside of the cell. In addition, using methods like that of Strehlow *et al.* (D. Strehlow et al., Proc. Natl. Acad. Sci. USA. 97: 4209-4214 (2000)), packaging cells such as PA317 can be infected with recombinant Moloney murine leukemia viruses, which are constructed using vectors derived from Moloney viruses into which exogenous protein-encoding genes have been introduced, and the exogenous proteins can be expressed on the envelope of viruses released outside of the cells. These are examples of viruses for expressing exogenous proteins and the viruses of the present invention that express exogenous proteins, useful as immunogens, are not limited to those that are constructed using the above methods.

20

30

35

40

45

50

[0036] Recombinant viruses constructed as described above can be purified using known methods, as necessary. For example, known methods for purifying viruses comprise augmented density gradient centrifugation (Albrechtsen et al., J. Virological Methods 28: 245-256 (1990); Hewish et al., J. Virological Methods 7: 223-228 (1983)), size exclusion chromatography (Hjorth and Mereno-Lopez, J. Virological Methods 5: 151-158 (1982); Crooks et al., J. Chrom. 502: 59-68 (1990); Mento S.J. (Viagene, Inc.) 1994 Williamsburg Bioprocessing Conference), affinity chromatography using monoclonal antibodies, sulphated fucose-containing polysaccharides and the like (Najayou et al., J. Virological Methods 32: 67-77 (1991); Diaco et al., J. Gen. Virol. 67: 345-351 (1986); Fowler, J. Virological Methods 11: 59-74 (1986); Japanese Patent Saikohyo Publication No. (JP-A) 97/032010 (unexamined Japanese national phase publication corresponding to a Japanese international publication)), and DEAE ion exchange chromatography (Haruna et al., Virology 13: 264-267 (1961)). Thus, purification can be carried out using the above methods or combinations thereof.

[0037] Animals to be immunized are immunized using immunogens prepared as described above. The immunized animals used in the present invention are nonhuman animals in which immunotolerance against a background antigen membrane protein comprised in an immunogen has been induced. Induction of immunotolerance against a background antigen membrane protein can be carried out as described above, by making animals to be immunized carry a gene encoding a soluble form of this membrane protein.

[0038] When a baculovirus expression system, which was shown above as an expression system suitable for membrane protein preparation, is used for immunogen preparation, preferably, nonhuman animals made to carry a gene encoding a soluble gp64 and induced to have immunotolerance against gp64 are used as the immunized animals. Herein, nonhuman animals carrying a gene encoding the full-length gp64 may be used as the immunized animals, however, the use of soluble gp64 transgenic animals and such is preferred since they can be widely used, and can be produced efficiently since both males and females are fertile. Therefore, for example, in a preferred embodiment of the present invention, nonhuman animals carrying a gene encoding a soluble gp64 are used as immunized animals, and a budding baculovirus made to express a membrane protein as the target antigen is used as the immunogen to carry out the immunizations.

[0039] By using the antibody-production methods of the present invention, the inhibitory effect on the acquisition of antibodies against a target antigen due to contamination of membrane proteins as background antigens can be suppressed. Consequently, the use of this invention enables sufficient application of the advantages of a baculovirus expression system as an exogenous protein expression system, even in the preparation of immunogens.

[0040] Well-known methods can be used for the methods of immunizing to obtain antibodies. Animals can be immunized with an immunogen using known methods. General methods comprise injecting a sensitizing antigen into a mammal by subcutaneous or intraperitoneal injection. Specifically, an immunogen is diluted with an appropriate volume of Phosphate-Buffered Saline (PBS), physiological saline, or such and as desired, the suspension is mixed with an appropriate volume of a conventional adjuvant. This is emulsified and administered to the mammals. For example, Freund's complete adjuvant can be used as an adjuvant. In addition, after this, an immunogen that has been mixed with an appropriate volume of Freund's incomplete adjuvant is preferably administered several times every four to 21 days. In this way

immunization occurs, and the increased level of a desired antibody in the serum can be confirmed using conventional methods.

[0041] An increase in the level of a desired antibody in the serum is confirmed, blood is collected from the immunized mammals, and the serum is separated. As polyclonal antibodies, serum comprising polyclonal antibodies can be used. Where necessary, fractions comprising polyclonal antibodies can be isolated from this serum, and this fraction can also be used.

[0042] Methods for producing monoclonal antibodies can be combined with the antibody production methods of the present invention. After confirming the increase in the level of the intended antibody in the serum of a mammal that was sensitized by the above-described antigen, the antibody-producing cells are extracted from the mammal and cloned to obtain monoclonal antibodies. Spleen cells and such can be used as antibody-producing cells. Antibody-producing cells can be cloned by cell fusion methods. Mammalian myeloma cells and such can be used as parent cells to be fused with the above-mentioned antibody-producing cells. Even more preferably, myeloma cells that comprise unique auxotrophy or drug resistance can be examples of useful selective markers for fusion cells (hybridoma cells). By basically following the methods known in the art, fusion cells can be obtained from the antibody-producing cells and the myeloma cells described above. Methods for producing monoclonal antibodies by using the cell fusion techniques have been established, for example, by Milstein *et al.* (Galfre, G. and Milstein, C., Methods Enzymol. (1981) 73, 3-46).

[0043] The hybridoma cells produced by cell fusion techniques are selected by culturing in a selective medium. A selective medium is chosen in accordance with the characteristic features and such of the myeloma cells used for the cell fusion. HAT medium (a medium comprising hypoxanthine, aminopterine, and thymidine), for example, can be used as a selective medium. The hybridoma cells are cultured in the HAT medium for a time sufficient to kill all cells other than the intended hybridoma cells (e.g. all non-fused cells). Generally, hybridoma cells can be selected by continuing culture for several days to several weeks. Then, a standard limiting dilution method is carried out to screen and clone the hybridoma cells that produce the subject antibodies.

[0044] Subsequently, the hybridoma cells thus obtained can be intraperitoneally transplanted into mice to obtain ascites fluid comprising the monoclonal antibodies. Monoclonal antibodies can also be purified from the ascites fluid. For example, monoclonal antibodies can be purified by ammonium sulfate precipitation methods, protein A or protein G columns, DEAE ion exchange chromatography, or affinity columns coupled with a target antigen.

[0045] Monoclonal antibodies obtained in this way can also be made into recombinant antibodies produced using gene recombination technologies (for example, see Borrebaeck, C.A.K. and Larrick, J.W., Therapeutic Monoclonal Antibodies, UK, Macmillan Publishers Ltd., 1990). Recombinant antibodies are produced by cloning the DNAs that encode them from antibody-producing cells, such as hybridomas and antibody-producing sensitized lymphocytes, then incorporating these DNAs into a suitable vector, and introducing this vector into a host.

30

35

40

45

50

55

[0046] Furthermore, antibody fragments and modified antibodies can be obtained by combining antibody alteration and modification techniques with the antibody production method of the present invention. For example, an antibody fragment can be an Fab, F(ab')2, Fv, or a single chain Fv (scFv) where the Fvs of an H chain and L chain are linked by a suitable linker (Huston, J.S. el al., Proc. Natl. Acad. Sci. U.S.A., (1988) 85, 5879-5883). Antibodies bound to various molecules such as polyethylene glycols (PEG), can also be used as the modified antibodies. Such modified antibodies can be obtained by chemically modifying the obtained antibodies. These methods have already been established in the art. [0047] The methods for producing antibodies of the present invention can be combined with modification techniques used for human antibodies. Human antibodies of interest can be obtained by using transgenic animals carrying the

used for human antibodies. Human antibodies of interest can be obtained by using transgenic animals carrying the complete repertoire of human antibody genes as a basis (see International Patent Application Publication Nos. WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735), introducing a gene encoding a soluble form of a background antigen, making them carry the ability to produce human antibodies and the immunotolerance against the background antigen, and immunizing them with a desired antigen.

[0048] The antibodies obtained by the methods of the present invention can be chimeric antibodies comprising non-human antibody-derived variable regions, derived from the immunized animals, and human antibody-derived constant regions. In addition, they can also be humanized antibodies comprising complementarity determining regions (CDRs) of non-human antibodies derived from the immunized animals and the framework regions (FRs) and constant regions derived from human antibodies. These modified antibodies can be produced using known methods. Specifically, for example, a chimeric antibody is an antibody comprising the antibody heavy chain and light chain variable regions of an immunized animal, and the antibody heavy chain and light chain constant regions of a human. A chimeric antibody can be obtained by (1) ligating a DNA encoding a variable region of an immunized animal-derived antibody to a DNA encoding a constant region of a human antibody; (2) incorporating this into an expression vector; and (3) introducing the vector into a host for production of the antibody.

[0049] A humanized antibody, which is also called a reshaped human antibody, is a modified antibody. A humanized antibody is constructed by transplanting a complementarity determining region (CDR) of an antibody derived from an immunized animal, into the CDR of a human antibody. Conventional genetic recombination techniques for the preparation of such antibodies are known.

[0050] Specifically, a DNA sequence designed to ligate a mouse antibody CDR with a human antibody framework region (FR) is synthesized by PCR, using several oligonucleotides constructed to comprise overlapping portions at their ends. A humanized antibody can be obtained by (1) ligating the resulting DNA to a DNA which encodes a human antibody constant region; (2) incorporating this into an expression vector; and (3) introducing the vector into a host to produce the antibody (see, European Patent Application Publication No. EP 239,400, and International Patent Application Publication No. WO 96/02576). Those human antibody FRs that are ligated via the CDR, such that the CDR forms a favorable antigen-binding site, are selected. As necessary, amino acids in the framework region of an antibody variable region may be substituted such that the CDR of a reshaped human antibody forms an appropriate antigen-binding site (Sato, K. et al., Cancer Res. (1993) 53, 851-856).

[0051] Furthermore, genes coding for the antibodies can be obtained from the antibody-producing cells of an immunized animal. Methods used to obtain genes that code for antibodies are not limited. For example, genes coding for antibodies can be obtained by amplification using the PCR method, by using as templates those genes that code for variable regions or CDRs. Primers for the amplification of genes that code for antibodies are known in the art. Subject antibodies can be produced by expressing genes thus obtained in an appropriate expression system. Alternatively, the genes obtained by the present invention can be utilized to produce various modified antibodies (chimeric antibodies comprising human antibody-derived constant regions and humanized antibodies in which the CDRs of an immunized animal-derived antibody is transplanted to the CDRs of a human antibody).

[0052] The present invention provides systems for antibody production that comprise nonhuman animals carrying a gene encoding a soluble form of a membrane protein.

[0053] When an immunogen is prepared using a viral expression vector, in certain cases, membrane proteins derived from that virus or from host cells into which the viral expression vector has been introduced may contaminate as background antigens. These background antigen membrane proteins are not products of the exogenous target antigen gene, and in most cases, they are derived from the expression system, such as from the vector or host. Therefore, the background antigen membrane proteins that may contaminate are identified for every expression system. Then, a gene encoding a soluble form of this membrane protein is introduced into nonhuman animals by transgenic techniques, and whether immunotolerance against the membrane protein has been induced is confirmed in the obtained transgenic animals. Whether or not immunotolerance has been induced in the nonhuman animals can be confirmed as indicated in the Examples, by confirming the production of antibodies against the background antigen membrane protein in the serum.

[0054] Because the background antigen membrane protein is expressed in its soluble form, the expression of unfavorable phenotypes, such as the loss of fertility in males observed with the baculovirus gp64, is avoided in these nonhuman animals in which the induction of immunotolerance against the background antigen has been confirmed; such animals may thus be provided as widely useful animals to be immunized. Therefore, systems that can support efficient antibody production can be constructed by combining the animals to be immunized that carry a gene encoding a soluble form of a membrane protein of the present invention with an expression system that produces this membrane protein as a background antigen.

[0055] For example, by combining a baculovirus expression system described in detail above with nonhuman animals carrying a gene encoding a soluble gp64, the advantages of a baculovirus expression system can be reflected in antibody production. More specifically, in a baculovirus expression system, desired proteins, particularly membrane proteins, can be expressed as target antigens along with gp64 while maintaining their three-dimensional structure, and the expression products can be easily collected as budding viruses. These budding viruses are used as the immunogens and immunization is performed on the nonhuman animals carrying a gene encoding a soluble gp64 as the immunized animals. Since immunotolerance against gp64 is induced in these nonhuman animals carrying a gene encoding a soluble gp64, even if a large amount of gp64 is expressed on the budding virus serving as the immunogen, antibody production against this gp64 is suppressed and antibodies against the membrane protein serving as the target antigen can be produced. Therefore, even when gp64 is present on a baculovirus as a background antigen, by using nonhuman animals carrying a gene encoding a soluble gp64, antibody production against the target antigen can be favorably induced. As a result, the antibodies obtainable by the present system will be extremely pure antibodies against the target antigen.

Examples

10

30

35

40

45

50

[Example 1] Construction of an sgp64 transgenic vector

[0057] The transmembrane region (nucleotides 1465 to 1539) was deleted from the gp64 gene (SEQ ID NO: 1; full length: 1539 bp) to prepare by PCR a gene fragment comprising only the extracellular region (soluble gp64; 1464 bp; SEQ ID NO: 3).

[0056] All prior art references cited herein are incorporated by reference into this description.

[0058] More specifically, a 5' primer in which the 5'-terminal sequence of gp64, the restriction enzyme EcoRI recognition

sequence, and a KOZAK sequence are linked (64F1: 5'-GAATTCCACCATGGTAAGCGCTATTGTT-3'; SEQ ID NO: 5); a 3' primer in which the EcoRI recognition sequence is 5'-end linked to the sequence immediately before the transmembrane region of gp64 (s64R1:

5'-GAATTCTCATTATACATGACCAAACATGAACGA-3'; SEQ ID NO: 6) (Fig. 1-a and Fig. 1-b); and the pCAG-qp64 vector serving as a template DNA were used, and a polymerase chain reaction (PCR) was performed under the following conditions: the composition of the PCR reaction solution was 5 μ L of 10x ExTaq buffer (TaKaRa), 4 μ L of dNTP mixture comprised in the ExTaq kit, 1 μL of 64F1 primer (10 μmole/L), 1 μL of s64R1 primer (10 μmole/L), 1 μL of pCAG-gp64 (500 pg/μL), 0.5 μL of ExTaq (5 units/μL, TaKaRa), and 37.5 μL of H₂O. The reaction was carried out by heating at 94°C for five minutes, and then performing 25 cycles of 94°C for 15 seconds, 57°C for 30 seconds, and 72°C for 30 seconds. The mixture was then treated at 72°C for seven minutes, and stored at 4°C. The amplified band was subcloned into pGEM-Teasy (Promega) and E. coli (DH5α, TOYOBO) were transformed with this. Colony PCR was performed using the T7 primer (5'-TAATACGACTCACTATA-3', SEQ ID NO: 7) and SP6 primer (5'-CATACGATTTAGGTGACAC-TATAG-3', SEQ ID NO: 8), the nucleotide sequences of clones found to carry the insert were analyzed with an ABI Prism 377 DNA sequencer using the BigDye Cycle Sequence kit (Applied Biosystems) and the T7 primer or the SP6 primer, and a clone carrying the desired gene was confirmed. The fragment comprising gp64 was cut out from this clone by EcoRI restriction enzyme treatment, inserted into pCAGGS vector treated with the restriction enzyme EcoRI, and E. coli (DH5 α) were transformed with this. The direction of insertion of the gp64 fragment was determined from the size of the band (approximately 2.1 kb) obtained by Xhol and Xbal restriction enzyme treatment and the pCAG-sgp64 vector was produced (Fig. 2). The clone as designed was cultured overnight at 37°C using 250 mL of LB medium and purified using Endofree MAXI kit (QIAGEN) to obtain the plasmid (581.6 of µg).

[Example 2] Establishment of sgp64Tgm

20

30

35

40

45

50

[0059] A DNA injection fragment for use in Tgm production was prepared by treating the pCAG-sgp64 vector with the restriction enzymes Sall and Pstl, then cutting out the fragment comprising the sgp64 gene (approximately 3.7 kb), collecting the fragment using a Gel Extraction Kit (QIAGEN), and then diluting this fragment to 3 ng/μL using PBS⁻. Mouse pronuclear stage embryos into which the DNA fragment was to be inserted were collected as follows: BALB/cA female mice (Japan Clea) were subjected to superovulation treatment (5 IU of eCG (Serotropin, Teikoku Zoki) was administered intraperitoneally, and 48 hours later, 5 IU of hCG (Puberogen, Sankyo) was administered intraperitoneally), and then mated with male mice of the same strain (Japan Clea). The next morning, the oviducts of female mice found to have a vaginal plug were perfused to collect the pronuclear stage embryos. The DNA fragment was injected into pronuclear stage embryos using a micromanipulator ("Modern Techniques in Gene Targeting" (Yodosha), 190-207, 2000). The following day, embryos that had developed to the two-cell stage were transplanted into the left and right oviducts of one-day pseudopregnant recipient females at ten or so embryos per oviduct (20 or so embryos per individual). Recipient females that did not deliver litters by the expected delivery date were subjected to caesarian section and the pups were nursed by foster parents.

[0060] Based on the above methods, the DNA fragment was injected into 497 BALB/cA pronuclear stage mice embryos, and of these the 430 that developed into two-cell stage embryos were transplanted into the oviducts of pseudopregnant recipient females. As a result, 66 pups were obtained. Gene introduction into the obtained pups was confirmed as described below.

[0061] The mouse tails were collected and treated at 55 °C overnight with Lysis buffer (50 mM Tris-HCl pH8.0, 0.1 M NaCl, 20 mM EDTA, 1% SDS, Proteinase K 1 mg/mL; TaKaRa). Genomic DNA was then extracted using an automatic nucleic acid isolation system (KURABO, NA-1000P), and the introduced gene was confirmed by Southern blotting and PCR. Confirmation of the introduced gene by Southern blotting was performed by treating the extracted genomic DNA (15 μg) with the restriction enzyme EcoRl, electrophoresing in an agarose gel, and transferring onto a nylon membrane (Hybond N+; Amersham) by the alkaline blotting method. An approximately 1.5 kb restriction enzyme EcoRl-treated fragment of the pCAG-sgp64 vector comprising sgp64 was used as a probe. This was labeled with ³²P and Southern blotting was performed by hybridizing it with the blotted genomic DNA. Hybridization was carried out overnight at 45 °C using 5x SSPE, 50% formamide, 5x Denhardt, and 0.5% SDS as the hybridization solution. The nylon membranes were washed in 2x SSC containing 0.1 % SDS at 65 °C for 30 minutes, and then in 1x SSC containing 0.1 % SDS at 65 °C for 30 minutes. Thereafter, signals were detected using BAS2000 (FUJIX).

[0062] Confirmation of the introduced gene by PCR was carried out using the above-mentioned 64F1 as the sense primer, and the above-mentioned s64R1 as the antisense primer, under the following conditions: the composition of the PCR reaction solution was 1 μ L of genomic DNA (100 ng/ μ L), 5 μ L of 10x ExTaq buffer (TaKaRa), 4 μ L of dNTP mixture comprised in the ExTaq kit, 1 μ L of 64F1 primer (10 μ mole/L), 1 μ L of s64R1 primer (10 μ mole/L), 0.5 μ L of ExTaq (5 units/ μ L, TaKaRa), and 37.5 μ L of H₂O. The reaction was carried out by heating at 94°C for five minutes, and then performing 35 cycles of 94°C for 15 seconds, 57°C for 30 seconds, and 72°C for 30 seconds; subsequently, the mixture was treated at 72°C for seven minutes, and then stored at 4°C. The amplified product was subjected to electrophoresis,

and the presence or absence of a band of approximately 1.5 kb was verified.

[0063] This method confirmed that three of the 66 pups were Tgm carrying the sgp64 gene (hereinafter, Tgm obtained by inserting the DNA fragment will be referred to as "founder mice") (Table 1). One of the three founder mice was male, and the other two were female.

Table 1

	Number of viable eggs/ number of eggs receiving injection	Number of eggs transplanted	Number of eggs implanted	Number of pups (female, male)	Number of weanlings (female, male)	Founder
1st	120/133	114	61	29 (15, 14)	28 (14, 14)	0
2nd	78/88	76	22	4 (2, 2)	4 (2, 2)	0
3rd	102/111	101	55	12 (7, 5)	11 (7,4)	1 female, 1 male
4th	130/165	126	64	21(11,10)	15 (8, 7)	1 female
Total	430/497	417	202	66(35,31)	58(31,27)	2 females, 1 male

[0064] When eight weeks old, the obtained founder mice were mated with BALB/cA mice. Specifically, of the three founder mice, 26 pups were obtained by mating the male founder mouse (line number 41) with five females, and of these pups, 12 were Tgm (F1 mice). Nine of the 16 pups obtained from the first female founder mouse (line number 36) were Tgm (F1 mice, including males and females), and four of these were males (Table 2). Eight of the 15 pups obtained from the other female founder mouse (line number 51) were Tgm (F1 mice, including males and females), and one of these was a male (Table 2).

Table 2

Line number	Sex	Number of deliveries	Litter size	Number of Tgm (F1)
36	Female	2	7 females, 9 males	5 females, 4 males
41	Male	5	11 females, 15 males	4 females, 8 males
51	Female	2	8 females, 7 males	7 females, 1 male

[Example 3] Fertility of male Tgm

[0065] The fertility of the male Tgm (F1 mice) obtained in Example 2 was examined. Fertility was confirmed by mating eight-week-old male sgp64Tgm (F1 mice) with BALB/cA mice, and confirming the presence and number of pups.

[0066] Male Tgm (F1 mice) obtained from each of the three founder lines (one animal from each line) were mated with two females to give nine pups (five females, four males), nine pups (two females, seven males), and ten pups (six females, four males) respectively, and of these, nine pups (five females, four males), eight pups (two females, six males), and five pups (four females, one male) were Tgm (Table 3). The male Tgm in all three lines were confirmed to have normal fertility.

Fertility results of male sgp64Tgm (F1 mice)

[0067]

5

10

15

20

30

35

40

45

50

55

Table 3

Line number	Number of deliveries	Litter size	Number of Tgm
36	2	5 females, 4 males	5 females, 4 males
41	2	2 females, 7 males	2 females, 6 males

(continued)

Line number	Number of deliveries	Litter size	Number of Tgm
51	2	6 females, 4 males	4 females, 1 male

[Example 4] Confirmation of tolerance to gp64 by Western blotting

[0068] To confirm induction of tolerance to gp64, sgp64Tgm were immunized with a budding baculovirus (pepT1-AcMNPV (pepT1-BV)), as set out below.

[0069] Immunization was carried out by producing an emulsion according to standard methods using Freund's complete adjuvant (Difco) and incomplete adjuvant (Difco), and administering it subcutaneously. The first immunizing dose was 1 mg/animal, and the second immunizing dose was 0.5 mg/animal. The second immunization was carried out 14 days after the first. After 17 days from the first immunization, blood was sampled from the orbit, and serum was collected. As controls, non-transgenic mice were immunized similarly, and their sera were collected.

[0070] The following Western blot analysis was carried out to confirm tolerance to gp64 in the Tgm:

pepT1-BV used as the antigen was subjected to SDS-PAGE at 1 μ g/lane using a 12% gel and under reducing conditions. After electrophoresis, electroblotting onto a PVDF membrane was carried out. The serum collected above was diluted to 1/1000, and reacted with this membrane, which was then washed three times for five minutes at room temperature using PBS-T (PBS containing 0.05% Tween20). After washing, biotin-anti-mouse $lgG(\gamma)$ (Zymed) diluted to 1/1000, and streptavidin-alkaline phosphatase (Zymed) were reacted with the membrane. Alkaline Phosphatase Staining Kit (Nakalai) was used for staining.

[0071] In the case of non-transgenic mice (non-Tgm), staining with anti-mouse IgG resulted in strong staining for all three mice (Fig. 3). On the other hand, there was hardly any gp64 staining for the sgp64Tgm, and this confirmed the induction of tolerance to gp64 in sgp64Tgm.

Industrial Applicability

5

10

15

20

25

30

35

40

45

50

55

[0072] The present invention provided new transgenic animals that overcome the problem of male infertility, which existed in conventional transgenic animals into which the gene for the baculovirus membrane protein gp64 had been introduced. The above-mentioned problem was solved by expressing a soluble gp64 (that is, expressing gp64 outside the cell membrane), which was prepared by methods such as deleting a sequence encoding the transmembrane region from the gene encoding the gp64 membrane protein. Therefore, the emergence of unfavorable phenotypes, such as the unfavorable characteristic of male infertility in transgenic animals into which a gene encoding a full-length membrane protein has been introduced, can be avoided in transgenic animals into which a gene encoding a soluble form of the membrane protein has been introduced, as in the present invention.

[0073] As described above, just as for transgenic animals into which genes encoding a full-length membrane protein had been introduced, transgenic animals into which genes encoding a soluble protein had been introduced have been confirmed to have induced immunotolerance to the membrane protein. Therefore, when the immunogens have contaminating membrane proteins as background antigens, it is advantageous to use, as animals to be immunized, the transgenic animals which carry genes encoding soluble proteins that lack a transmembrane region, and such, of these membrane proteins as exogenous genes. That is, since immunotolerance against background antigen membrane proteins is induced, antibodies specific to the desired antigen are produced advantageously, and since unfavorable phenotypes of transgenic animals into which the full-length membrane protein has been introduced can be avoided in these immunized animals, they will be utilized even more readily as systems for antibody production.

[0074] The antibodies produced using the animals of the present invention are not contaminated or very slightly contaminated by antibodies against background antigens, and they are therefore provided as highly pure antibodies.

SEQUENCE LISTING

5	<110>	CHUG	A I SE	EIYAF	KU KA	ABUSH	HIKI	KAIS	SHA									
	<120>	Nonh	uman	ani	mal	for	con	stru	cting	g an	t i bo	dy a	ınd	metho	d and	system	of	constructing
10	antibo	dy us	ing	the	same													
	<130>	C1-AI	0326	•														
15	<150>	JP200	N4-11	7669	9													
	<151>																	
20	<160>	10																
	<170>	Pate	ntln	vers	sion	3. 1												
25	<210>	1																
	<211>	1539																
	<212>	DNA																
30	<213>	Bacu	lovi	rus														
	<220>																	
	<221>	CDS																
35	<222>	(1)	(15	39)														
	<223>																	
40	<400>	1																
	atg gt	a agc	gct	att	gtt	tta	tat	gtg	ctt	ttg	gcg	gcg	gcg	gcg	cat	48		
	Met Va	l Ser	Ala	He	Val	Leu	Tyr	Val	Leu	Leu	Ala	Ala	Ala	Ala	His			
	1			5					10					15				
45																		
	tct go	c ttt	gcg	gcg	gag	cac	tgc	aac	gcg	caa	atg	aag	acg	ggt	ccg	96		
	Ser Al	a Phe	Ala	Ala	Glu	His	Cys	Asn	Ala	Gln	Met	Lys	Thr	Gly	Pro			
50			20					25					30					
	tac aa	g att	aaa	aac	ttg	gac	att	acc	ccg	ccc	aag	gaa	acg	ctg	caa	144		
	Tyr Ly	's lle	Lys	Asn	Leu	Asp	He	Thr	Pro	Pro	Lys	Glu	Thr	Leu	GIn			
55																		

			35					40					45				
5													aac				192
	Lys	Asp	Val	Glu	He	Thr	He	Val	Glu	Thr	Asp		Asn	Glu	Asn	Val	
		50					55					60					
10																	0.40
													tac -				240
		He	Gly	Tyr	Lys		Tyr	Tyr	GIn	Ala		Ala	Tyr	Asn	Gly		
15	65					70					75					80	
		. 4						~1~	~~~	~~•					0 t 0	20+	288
													aaa				200
	ser	Leu	ASP	Pro	85	1111	Arg	vai	GIU	90	1111	MEL	Lys	1111	95	Wall -	
20					00					30					33		
	øtø	aac	aaa	gag	gat	ttø	ctt	atg	tgg	agc	atc	agg	cag	cag	tgc	gag	336
													Gln				
25		,	-,,	100				•	105					110			
	gtg	ggc	gaa	gag	ctg	atc	gac	cgt	tgg	ggc	agt	gac	agc	gac	gac	tgt	384
30													Ser			_	
			115					120					125				
35	ttt	cgc	gac	aac	gag	ggc	cgc	ggc	cag	tgg	gtc	aaa	ggc	aaa	gag	ttg	432
	Phe	Arg	Asp	Asn	Glu	Gly	Arg	Gly	Gln	Trp	Val	Lys	Gly	Lys	Glu	Leu	
		130					135					140					
40													acg				480
	Val	Lys	Arg	Gln	Asn		Asn	His	Phe	Ala			Thr	Cys	Asn		
	145					150					155					160	
45																	500
													agc				528
	Ser	lrp	Arg	Cys		He	Ser	Ihr	Ser			ıyr	Ser	Arg			
50					165					170					175		
	+~-		~	~~~	000	ma.c	~ ~~	+~~		~+ ^	+	2++	++~	400	ac+	asa.	576
													ttg				310
<i></i>	υyS	นเก	АЅР	180		v2h	GIU	Uy S	185		ıyf	116	Leu	190		aiu	
55				100					100					130			

5				atc lle												624
10		_		att He												672
15				tgt Cys												720
20				gaa Glu												768
30				tgg Trp 260												816
35			Arg	gtc Val				Pro	ccc			His	aac			864
40				aca Thr												912
45			gag	gag Glu								aaa				960
50		ctg	_	cat			atc		_		aat					1008
	618	Leu	мет	His	325	піЅ	ııe	wsn	LYS	330	หรถ	MET	Leu	335	W2h	

					gtg Val												1056
5	LCu	116	Vai	340	Vai	MIA	Lys	Vai	345	uru	AIG	Leu	116	350	VOII	Leu	
					gtt Val												1104
10	INICL	ASII	355	JUI	Vai	301	JCI	360	THE	LCu	JUI	ЛЭР	365		7110	Luu	
15					acc Thr												1152
	Leu	370	FIU	Cys	1111	MSII	375	FIU	МІА	піз	1111	380	ASII	Cys	I y i	ASII	
20					aaa												1200
	385	261	iie	ıyı	Lys	390	ыу	Arg	irp	Vai	395	ASII	1111	ASP	ser	400	
25					ttt												1248
	GIn	Cys	He	Asp	Phe 405	Ser	Asn	Tyr	Lys	Glu 410	Leu	Ala	lle	Asp	Asp 415	Asp	
30																	
					atc												1296
35	vai	GIU	rne	420	He	Pro	ınr	ile	425	ASTI	inr	Inr	ıyr	430	ASP	ser	
					agc												1344
40	Trp	Lys	Asp 435	Ala	Ser	Gly	Trp	Ser 440	Phe	lle	Ala	GIn	GIn 445	Lys	Ser	Asn	
	ctc	ata	асс	acc	atg	gag	aac	acc	aag	ttt	ggc	ggc	gtc	ggc	acc	agt	1392
45	Leu	l ∣e 450	Thr	Thr	Met	Glu	Asn 455	Thr	Lys	Phe	Gly	Gly 460	Val	Gly	Thr	Ser	
50	ctg	agc	gac	atc	act	tcc	atg	gct	gaa	ggc	gaa	ttg	gcc	gct	aaa	ttg	1440
50	Leu 465	Ser	Asp	He	Thr	Ser 470	Met	Ala	Glu	Gly		Leu	Ala	Ala	Lys	Leu 480	
	400					410					475					400	
55	act	tcg	ttc	atg	ttt	ggt	cat	gta	gtt	aac	ttt	gta	att	ata	tta	att	1488

	Thr Ser Pl	ne Met Ph 48		s Val Val	Asn Phe Val 490	lle lle Leu 495	
10					aga aac cgt Arg Asn Arg		
	taa						1539
15							
20	<210> 2 <211> 51: <212> PR <213> Ba	Т	3				
25	<400> 2 Met Val S	er Ala II 5	e Val Leu	u Tyr Val	Leu Leu Ala 10	Ala Ala Ala 15	a His
30	Ser Ala P	he Ala A 20	la Glu His	s Cys Asn 25	Ala GIn Met	Lys Thr GI:	y Pro
35	Tyr Lys I		sn Leu Asp	p lle Thr 40	Pro Pro Lys	Glu Thr Le	u Gin
40	Lys Asp V 50	al Glu I	le Thr IIo 55	e Val Glu	Thr Asp Tyr	Asn Glu As	n Val
45	lle lle G 65	ly Tyr L	ys Gly Tyr 70	r Tyr Gln	Ala Tyr Ala 75	Tyr Asn Gl	y Gly 80
50	Ser Leu A	sp Pro A: 8		g Val Glu	Glu Thr Met 90	Lys Thr Le 95	u Asn
	Val Gly L	ys Glu A: 100	sp Leu Lei	u Met Trp 105	Ser lle Arg	Gin Gin Cy 110	s Glu
55							

_	Val	Gly	GIu 115	Glu	Leu	lle	Asp	Arg 120	Trp	Gly	Ser	Asp	Ser 125	Asp	Asp	Cys
5	Phe	Arg 130	Asp	Asn	Glu	Gly	Arg 135	Gly	GIn	Trp	Val	Lys 140	Gly	Lys	Glu	Leu
10	Va I 145	Lys	Arg	Gln	Asn	Asn 150	Asn	His	Phe	Ala	His 155	His	Thr	Cys	Asn	Lys 160
15	Ser	Trp	Arg	Cys	Gly 165	He	Ser	Thr	Ser	Lys 170	Met	Tyr	Ser	Arg	Leu 175	Glu
20	Cys	Gln	Asp	Asp 180	Thr	Asp	Glu	Cys	GIn 185	Val	Tyr	He	Leu	Asp 190	Ala	Glu
25	Gly	Asn	Pro 195	He	Asn	Val	Thr	Va I 200	Asp	Thr	Val	Leu	His 205	Arg	Asp	Gly
30	Val	Ser 210	Met	He	Leu	Lys	GIn 215	Lys	Ser	Thr	Phe	Thr 220	Thr	Arg	GIn	lle
35	Lys 225	Ala	Ala	Cys	Leu	Leu 230	He	Lys	Asp	Asp	Lys 235	Asn	Asn	Pro	Glu	Ser 240
40	Val	Thr	Arg	Glu	His 245	Cys	Leu	lle	Asp	Asn 250	Asp	He	Tyr	Asp	Leu 255	Ser
	Lys	Asn	Thr	Trp 260	Asn	Cys	Lys	Phe	Asn 265	Arg	Cys	He	Lys	Arg 270	Lys	Val
45	Głu	His	Arg 275	Val	Lys	Lys	Arg	Pro 280	Pro	Thr	Trp	Arg	His 285	Asn	Val	Arg
50	Ala	Lys 290	Tyr	Thr	Glu	Gly	Asp 295	Thr	Ala	Thr	Lys	Gly 300	Asp	Leu	Met	His
55	lle	Gln	Glu	Glu	Leu	Met	Tyr	Glu	Asn	Asp	Leu	Leu	Lys	Met	Asn	Пe

	305			310					315					320
5	Glu Le	u Met His	325	His	Пe	Asn	Lys	Leu 330	Asn	Asn	Met	Leu	His 335	Asp
10	Leu II	e Val Se 34		Ala	Lys	Val	Asp 345	Glu	Arg	Leu	lle	Gly 350	Asn	Leu
15	Met As	n Asn Se 355	^r Val	Ser	Ser	Thr 360	Phe	Leu	Ser	Asp	Asp 365	Thr	Phe	Leu
20	Leu Me 37	t Pro Cy O	S Thr	Asn	Pro 375	Pro	Ala	His	Thr	Ser 380	Asn	Cys	Tyr	Asn
25	Asn Se 385	r lle Ty	′ Lys	Glu 390	Gly	Arg	Trp	Val	Ala 395	Asn	Thr	Asp	Ser	Ser 400
	GIn Cy	s lle As	Phe 405	Ser	Asn	Tyr	Lys	GI u 410	Leu	Ala	lle	Asp	Asp 415	Asp
30	Val GI	u Phe Tr 42		Pro	Thr	lle	GIy 425	Asn	Thr	Thr	Tyr	His 430	Asp	Ser
35	Trp Ly	s Asp Al 435	a Ser	Gly	Trp	Ser 440	Phe	lle	Ala	Gln	GIn 445	Lys	Ser	Asn
40	Leu 45	e Thr Th O							Gly			Gly	Thr	Ser
45	Leu Se 465	r Asp II	e Thr	Ser 470	Met	Ala	Glu	Gly	Glu 475	Leu	Ala	Ala	Lys	Leu 480
50	Thr Se	r Phe Me	t Phe 485	Gly	His	Val	Val	Asn 490	Phe	Val	lle	lle	Leu 495	lle
55	Val II	e Leu Ph 50		Tyr	Cys	Met	11e 505		Asn	Arg	Asn	Arg 510		Tyr

5	<21	0>	3														
	<21	1>	1464														
	<21	2>	DNA														
10	<21	3>	Bacu	lovi	rus												
	<220	0>															
	<22	1>	CDS														
15	<22	2>	(1)	(14	64)												
	<223	3>															
20	<400	0>	3														
	atg	gta	agc	gct	att	gtt	tta	tat	gtg	ctt	ttg	gcg	gcg	gcg	gcg	cat	48
	Met	Val	Ser	Ala	He	Val	Leu	Tyr	Val	Leu	Leu	Ala	Ala	Ala	Ala	His	
25	1				5					10					15		
	tct	gcc	ttt	gcg	gcg	gag	cac	tgc	aac	gcg	caa	atg	aag	acg	ggt	ccg	96
	Ser	Ala	Phe	Ala	Ala	Glu	His	Cys	Asn	Ala	GIn	Met	Lys	Thr	Gly	Pro	
30				20					25					30			
	tac	aag	att	aaa	aac	ttg	gac	att	асс	ccg	ccc	aag	gaa	acg	ctg	caa	144
			He														
35			35					40					45				
	aag	gac	gtg	gaa	atc	acc	atc	gtg	gag	acg	gac	tac	aac	gaa	aac	gtg	192
40	Lys	Asp	Val	Glu	He	Thr	He	Val	Glu	Thr	Asp	Tyr	Asn	Glu	Asn	Val	
		50					55					60					
45	att	atc	ggc	tac	aag	ggg	tac	tac	cag	gcg	tat	gcg	tac	aac	ggc	ggc	240
45	He	He	Gly	Tyr	Lys	Gly	Tyr	Tyr	Gln	Ala	Tyr	Ala	Tyr	Asn	Gly	Gly	
	65					70					75					80	
50	tcg	ctg	gat	ccc	aac	aca	cgc	gtc	gaa	gaa	асс	atg	aaa	acg	ctg	aat	288
	Ser	Leu	Asp	Pro	Asn	Thr	Arg	Val	Glu	Glu	Thr	Met	Ļys	Thr	Leu	Asn	
					85					90					95		

5		ggc Gly			_	_											336
10		ggc Gly															384
15		cgc Arg 130															432
20		aag Lys															480
25		tgg Trp															528
35		cag Gln															576
40		aac Asn															624
45		agt Ser 210															672
50		gct Ala		_					_	_							720
55	gtg	aca	cgc	gaa	cac	tgt	ttg	att	gac	aat	gat	ata	tat	gat	ctt	tct	768

	Val	Thr	Arg	Glu	His 245	Cys	Leu	He	Asp	Asn 250	Asp	He	Tyr	Asp	Leu 255	Ser	
5																	
	aaa	aac	acg	tgg	aac	tgc	aag	ttt	aac	aga	tgc	att	aaa	cgc	aaa	gtc	816
	Lys	Asn	Thr		Asn	Cys	Lys	Phe	Asn	Arg	Cys	Пe	Lys	Arg	Lys	Val	
10				260					265					270			
					aag												864
15	Glu	His		Val	Lys	Lys	Arg		Pro	Thr	Trp	Arg		Asn	Val	Arg	
			275					280					285				
																	010
					gag												912
20	АТА	290	ıyr	ınr	Glu	ыу		Inr	АГа	inr	Lys		ASP	Leu	Met	ніѕ	
		290					295					300					
	att	caa	asa	asa	ctg	2 † 07	tac	gaa	220	ast	++ <i>a</i>	cta	222	ata	220	2++	960
25					Leu												300
	305	uiii	UIU	uiu	LCU	310	131	uiu	VOII	V2h	315	Leu	Lys	MC	дэн	320	
	000					0.0					010					020	
30	gag	ctg	atg	cat	gcg	cac	atc	aac	aag	cta	aac	aat	atg	ctg	cac	gac	1008
					Ala												
					325					330					335	•	
95																	
35	ctg	ata	gtc	tcc	gtg	gcc	aag	gtg	gac	gag	cgt	ttg	att	ggc	aat	ctc	1056
	Leu	He	Val	Ser	Val	Ala	Lys	Val	Asp	Glu	Arg	Leu	He	Gly	Asn	Leu	
				340					345					350			
40																	
	atg	aac	aac	tct	gtt	tct	tca	aca	ttt	ttg	tcg	gac	gac	acg	ttt	ttg	1104
	Met	Asn	Asn	Ser	Val	Ser	Ser	Thr	Phe	Leu	Ser	Asp	Asp	Thr	Phe	Leu	
45			355					360					365			•	
	ctg	atg	ccg	tgc	acc	aat	ccg	ccg	gca	cac	acc	agt	aat	tgc	tac	aac	1152
50	Leu		Pro	Cys	Thr	Asn	Pro	Pro	Ala	His	Thr	Ser	Asn	Cys	Tyr	Asn	
50		370					375					380					
					aaa												1200
55	Asn	Ser	He	Гуr	Lys	Glu	Gly	Arg	Trp	Val	Ala	Asn	Thr	Asp	Ser	Ser	

	385	390	395	400
5		t agc aac tac aag gaa e Ser Asn Tyr Lys Glu 5 410	Leu Ala IIe Asp Asp	
10	gtc gag ttt tgg ato	c ccg acc atc ggc aac e Pro Thr Ile Gly Asn	acg acc tat cac gac Thr Thr Tyr His Asp	
15	420	425	430	
20		c ggc tgg tcg ttt att r Gly Trp Ser Phe Ile 440		
25		g gag aac acc aag ttt t Glu Asn Thr Lys Phe 455		
30		t tcc atg gct gaa ggc r Ser Met Ala Glu Gly 470		
35	act tcg ttc atg tt Thr Ser Phe Met Ph 48	e Gly His Val		1464
40	(010)			
45	<210> 4 <211> 488 <212> PRT <213> Baculovirus			
50	<400> 4 Met Val Ser Ala II 1 5	e Val Leu Tyr Val Leu 10	ı Leu Ala Ala Ala Ala 15	His
55	Ser Ala Phe Ala Al	a Glu His Cys Asn Ala	ı Gln Met Lys Thr Gly	Pro

				20					25					30		
5	Tyr	Lys	11e 35	Lys	Asn	Leu	Asp	11e 40	Thr	Pro	Pro	Lys	G1u 45	Thr	Leu	GIn
10	Lys	Asp 50	Val	Glu	lle	Thr	11e 55	Val	Glu	Thr	Asp	Tyr 60	Asn	Glu	Asn	Val
15	11e 65	lle	Gly	Tyr	Lys	Gly 70	Tyr	Tyr	GIn	Ala	Tyr 75	Ala	Tyr	Asn	Gly	Gly 80
20	Ser	Leu	Asp	Pro	Asn 85	Thr	Arg	Val	Glu	Glu 90	Thr	Met	Lys	Thr	Leu 95	Asn
25	Val	Gly	Lys	Glu 100	Asp	Leu	Leu	Met	Trp 105	Ser	lle	Arg	GIn	GIn 110	Cys	Glu
30	Val	Gly	Glu 115	Glu	Leu	He	Asp	Arg 120	Trp	Gly	Ser	Asp	Ser 125	Asp	Asp	Cys
	Phe	Arg 130	Asp	Asn	Glu	Gly	Arg 135	Gly	GIn	Trp	Val	Lys 140	Gly	Lys	Glu	Leu
35	Va I 145	Lys	Arg	GIn	Asn	Asn 150	Asn	His	Phe	Ala	His 155	His	Thr	Cys	Asn	Lys 160
40	Ser	Trp	Arg	Cys	Gly 165	He	Ser	Thr	Ser	Lys 170	Met	Tyr	Ser	Arg	Leu 175	Glu
45	Cys	GIn	Asp	Asp 180	Thr	Asp	Glu	Cys	GIn 185	Val	Tyr	ile	Leu	Asp 190	Ala	Glu
50	Gly	Asn	Pro 195	lle	Asn	Val	Thr	Va I 200	Asp	Thr	Val	Leu	His 205	Arg	Asp	Gly
55	Val	Ser 210	Met	lle	Leu	Lys	GIn 215	Lys	Ser	Thr	Phe	Thr 220	Thr	Arg	Gln	lle

	Lys	Ala	Ala	Cys	Leu	Leu	He	Lys	Asp	Asp	Lys	Asn	Asn	Pro	Glu	Ser
5	225					230					235					240
10	Val	Thr	Arg	Glu	His 245	Cys	Leu	He	Asp	Asn 250	Asp	He	Tyr	Asp	Leu 255	Ser
15	Lys	Asn	Thr	Trp 260	Asn	Cys	Lys	Phe	Asn 265	Arg	Cys	lle	Lys	Arg 270	Lys	Val
	Glu	His	Arg 275	Val	Lys	Lys	Arg	Pro 280	Pro	Thr	Trp	Arg	His 285	Asn	Val	Arg
20	Ala	Lys 290	Tyr	Thr	Glu	Gly	Asp 295	Thr	Ala	Thr	Lys	Gly 300	Asp	Leu	Met	His
25	11e 305	GIn	Glu	Glu	Leu	Met 310	Tyr	Glu	Asn	Asp	Leu 315	Leu	Lys	Met	Asn	11e 320
30	Glu	Leu	Met	His	Ala 325	His	He	Asn	Lys	Leu 330	Asn	Asn	Met	Leu	His 335	Asp
35	Leu	He	Val	Ser 340	Val	Ala	Lys	Val	Asp 345	Glu	Arg	Leu	lle	Gly 350	Asn	Leu
40	Met	Asn	Asn 355	Ser	Val	Ser	Ser	Thr 360	Phe	Leu	Ser	Asp	Asp 365	Thr	Phe	Leu
45	Leu	Met 370	Pro	Cys	Thr	Asn	Pro 375	Pro	Ala	His	Thr	Ser 380	Asn	Cys	Tyr	Asn
	Asn 385	Ser	He	Tyr	Lys	G1u 390	Gly	Arg	Trp	Val	Ala 395	Asn	Thr	Asp	Ser	Ser 400
	Gln	Cys	lle	Asp	Phe 405	Ser	Asn	Tyr	Lys	Glu 410	Leu	Ala	He	Asp	Asp 415	Asp
55																

	Val Glu	Phe Trp lle 420	Pro Thr Ile	Gly Asn Thr 425	Thr Tyr His A	Asp Ser
5	Trn I vs	Asn Ala Ser	Gly Trp Ser	·Phe lle Ala	Gin Gin Lys	Ser Asn
	TIP LYS	435	440		445	
10	Leu lle	Thr Thr Met	Glu Asn Thr	· Lys Phe Gly	Gly Val Gly	Thr Ser
	450		455		460	
15	Leu Ser	Asp IIe Thr	Ser Met Ala	a Glu Gly Glu	Leu Ala Ala	
	465		470	475	i	480
20	Thr Ser	Phe Met Phe	Gly His Val	l		
		485				
25	<210>	5				
		28				
		DNA				
30		Artificial				
	(210)	AT CITICIAI				
	<220>					
35	<223>	an artificia	lly synthes	ized primer s	sequence	
	<400>	5				
40	gaattcc	acc atggtaag	cg ctattgtt			
40						
	⟨210⟩	6				
45	⟨211⟩	33				
	<212>	DNA				
	<213>	Artificial				
50	<220>					
	<223>	an artificia	lly synthes	ized primer :	sequence	
55	<400>	6				

	gaatte	ctcat tatacatgac caaacatgaa cga	33
5			
	<210>	7	
	⟨211⟩	17	
40	<212>	DNA	
10	<213>	Artificial	
	<220>		
15	<223>	an artificially synthesized primer sequence	
	<400>	7	
20	taatao	cgact cactata	17
0.5	<210>		
25	<211>		
	<212>		
	<213>	Artificial	
30	(000)		
	<220>		
	(223)	an artificially synthesized primer sequence	
35	<400>	8	
	catacg	gattt aggtgacact atag	24
40			
	<210>	9	
		1486	
45	<212>	DNA	
	<213>	Baculovirus	
50			
	<220>		
	<221>	CDS	
55	<222>	(2) (1474)	

	<400)> 9)														
5	g aa	it to	c ac	c at	g gt	a ag	c gc	t at	t gt	t tt	a ta	t gt	g ct	t tt	g gc	g gcg	49
	As	n Se	r Th	ır Me	t Va	I Se	r Al	a II	e Va	l Le	u Ty	r Va	l Le	u Le	u Al	a Ala	
	1				5					10)				15		
10																	
	gcg	gcg	cat	tct	gcc	ttt	gcg	gcg	gag	cac	tgc	aac	gcg	caa	atg	aag	97
	Ala	Ala	His	Ser	Ala	Phe	Ala	Ala	Glu	His	Cys	Asn	Ala	GIn	Met	Lys	
15				20					25					30			
75																	
					aag												145
	Thr	Gly	Pro	Tyr	Lys	He	Lys	Asn	Leu	Asp	Нe	Thr	Pro	Pro	Lys	Glu	
20			35					40					45				
					gac												193
25	Thr	Leu	Gln	Lys	Asp	Val		He	Thr	He	Val		Thr	Asp	Tyr	Asn	
		50					55					60					
																	0.41
00					atc												241
30		Asn	Val	He	He		Tyr	Lys	Gly	lyr		GIn	Ala	ıyr	Ala		
	65					70					75					80	
															. + ~		289
35					ctg												209
	Asn	Gly	Gly	Ser	Leu	Asp	Pro	ASN	ınr		vai	GIU	GIU	ınr		LyS	
					85					90					95		
40					~~~		~^~	~a +	***		a t m	taa	200	atr	200	L 3 G	337
					ggc Gly												001
	ınr	Leu	W2II			L y S	Giu	Vah	105		IVIC	קוו	301	110		0111	
45				100					103								
45	cag	tar	. 020	ata	ggc	gaa	gag	cto	atc	gac.	cet	tgg	ggo	agt	gac	agc	385
					Gly												
	um	uy s	115		utj	uiu	uju	120		7100	,,,,		125				
50			113					0					•				
	gar	gar	† e †	†††	cgc	gan	aac	gae	ggo	CEC	ggo	cag	tgs	gto	: aaa	ggc	433
					Arg												
55		130					135			0		140			-	-	

5			_		aag Lys		_										481
	145	GIU	Leu	Vai	Lys	150	uiii	ASII	VOII	7311	155	riic	ЛІА	1113	1113	160	
10	-				tgg												529
	Cys	Asn	Lys	Ser	Trp 165	Arg	LYS	GIY	116	5er 170	Inr	Ser	LYS	мет	175	Ser	
15	agg	ctc	gag	tgc	cag	gac	gac	acg	gac	gag	tgc	cag	gta	tac	att	ttg	577
	Arg	Leu	Glu	Cys 180	Gin	Asp	Asp	Thr	Asp 185	Glu	Cys	Gln	Val	Tyr 190	He	Leu	
20																	
	gac	gct	gag	ggc	aac	ССС	atc	aac	gtg	acc	gtg	gac	act	gtg	ctt	cat	625
	Asp	Ala		Gly	Asn	Pro	Пe	Asn	Val	Thr	Val	Asp	Thr	Val	Leu	His	
25			195					200					205				
	cga	gac	ggc	gtg	agt	atg	att	ctc	aaa	caa	aag	tct	acg	ttc	асс	acg	673
					Ser												
30		210					215					220					
	cgc	caa	ata	aaa	gct	gcg	tgt	ctg	ctc	att	aaa	gat	gac	aaa	aat	aac	721
35	Arg	GIn	He	Lys	Ala	Ala	Cys	Leu	Leu	He	Lys	Asp	Asp	Lys	Asn	Asn	
	225					230					235					240	
	ccc	gag	tcg	gtg	aca	cgc	gaa	cac	tgt	ttg	att	gac	aat	gat	ata	tat	769
40	Pro	Glu	Ser	Val	Thr	Arg	Glu	His	Cys	Leu	He	Asp	Asn	Asp	He	Tyr	
					245					250					255		
45	gat	ctt	tct	aaa	aac	acg	tgg	aac	tgc	aag	ttt	aac	aga	tgc	att	aaa	817
	Asp	Leu	Ser	Lys	Asn	Thr	Trp	Asn	Cys	Lys	Phe	Asn	Arg	Cys	Пe	Lys	
				260					265					270			
50	cgc	aaa	gtc	gag	cac	cga	gtc	aag	aag	cgg	ccg	CCC	act	tgg	cgc	cac	865
	Arg	Lys	Val	Glu	His	Arg	Val	Lys	Lys	Arg	Pro	Pro	Thr	Trp	Arg	His	
			275					280					285				
55																	

5		gtt Val 290															913
10	_	atg Met															961
15	_	aac Asn															1009
20		cac His															1057
25		aat Asn															1105
30		ttt Phe 370											His				1153
40		tac Tyr															1201
45		tcg Ser															1249
50	_	gac Asp	_	_					_			_					1297
55	cac	gac	agt	tgg	aaa	gat	gcc	agc	ggc	tgg	tcg	ttt	att	gcc	caa	caa	1345

5	His Asp Ser Trp Lys Asp Ala Ser Gly Trp Ser Phe IIe Ala Gln Gln 435 440 445	
10	aaa agc aac ctc ata acc acc atg gag aac acc aag ttt ggc ggc gtc Lys Ser Asn Leu lie Thr Thr Met Glu Asn Thr Lys Phe Gly Gly Val 450 455 460	}
15	ggc acc agt ctg agc gac atc act tcc atg gct gaa ggc gaa ttg gcc Gly Thr Ser Leu Ser Asp lle Thr Ser Met Ala Glu Gly Glu Leu Ala 465 470 475 480	
20	gct aaa ttg act tcg ttc atg ttt ggt cat gta taatgagaat tc 1486 Ala Lys Leu Thr Ser Phe Met Phe Gly His Val 485 490)
25	<210> 10 <211> 491 <212> PRT	
30	<213> Baculovirus <400> 10	
35	Asn Ser Thr Met Val Ser Ala IIe Val Leu Tyr Val Leu Leu Ala Ala 1 5 10 15	
40	Ala Ala His Ser Ala Phe Ala Ala Glu His Cys Asn Ala Gln Met Lys 20 25 30	
45	Thr Gly Pro Tyr Lys lie Lys Asn Leu Asp lie Thr Pro Pro Lys Glu 35 40 45	
55	Thr Leu Gin Lys Asp Val Giu ile Thr ile Val Giu Thr Asp Tyr Asn 50 55 60	

5	GIu 65	Asn	Val	lle	lle	Gly 70	Tyr	Lys	Gly	Tyr	Tyr 75	GIn	Ala	Tyr	Ala	Tyr 80
10	Asn	Gly	Gly	Ser	Leu 85	Asp	Pro	Asn	Thr	Arg 90	Val	Glu	Glu	Thr	Met 95	Lys
15	Thr	Leu	Asn	Val 100	Gly	Lys	Glu	Asp	Leu 105	Leu	Met	Trp	Ser	lle 110	Arg	Gin
20	Gin	Cys	G I u 115	Val	Gly	Glu	Glu	Leu 120	ile	Asp	Arg	Trp	Gly 125	Ser	Asp	Ser
30	Asp	Asp 130	Cys	Phe	Arg	Asp	Asn 135	Glu	Gly	Arg	Gly	GIn 140	Trp	Val	Lys	Gly
35	Lys 145	Glu	Leu	Val	Lys	Arg 150	GIn	Asn	Asn	Asn	His 155	Phe	Ala	His	His	Thr 160
40	Cys	Asn	Lys	Ser	Trp 165	Arg	Cys	Gly	lle	Ser 170	Thr	Ser	Lys	Met	Tyr 175	Ser
45	Arg	Leu	Glu	Cys 180	Gin	Asp	Asp	Thr	Asp 185	Glu	Cys	Gln	Val	Tyr 190	lle	Leu
55	Asp	Ala	GIu 195	Gly	Asn	Pro	lle	Asn 200	Val	Thr	Val	Asp	Thr 205	Val	Leu	His
55																

5	Arg	Asp 210	Gly	Val	Ser	Met	11e 215	Leu	Lys	GIn	Lys	Ser 220	Thr	Phe	Thr	Thr
10	Arg 225	Gin	He	Lys	Ala	Ala 230	Cys	Leu	Leu	lle	Lys 235	Asp	Asp	Lys	Asn	Asn 240
15	Pro	Glu	Ser	Val	Thr 245	Arg	Glu	His	Cys	Leu 250	He	Asp	Asn	Asp	11e 255	Tyr
20	Asp	Leu	Ser	Lys 260	Asn	Thr	Trp	Asn	Cys 265	Lys	Phe	Asn	Arg	Cys 270	lle	Lys
25	Arg	Lys	Val 275	Glu	His	Arg	Val	Lys 280	Lys	Arg	Pro	Pro	Thr 285	Trp	Arg	His
35	Asn	Va I 290	Arg	Ala	Lys	Tyr	Thr 295	Glu	Gly	Asp	Thr	Ala 300	Thr	Lys	Gly	Asp
40	Leu 305	Met	His	He	Gin	Glu 310	Glu	Leu	Met	Tyr	Glu 315	Asn	Asp	Leu	Leu	Lys 320
45	Met	Asn	lle	Glu	Leu 325	Met	His	Ala	His	11e 330	Asn	Lys	Leu	Asn	Asn 335	Met
50	Leu	His	Asp	Leu 340	le	Val	Ser	Val	Ala 345	Lys	Val	Asp	Glu	Arg 350	Leu	lle
55																

	Gly	Asn	Leu 355	Met	Asn	Asn	Ser	Va I 360	Ser	Ser	Thr	Phe	Leu 365	Ser	Asp	Asp
5	Th.	n h a	1	Lau	H-4	Dwa	Cur	Th		Dua	Dua	Ala	II: a	Th.	Ca.	A a
10	. inr	9he 370	Leu	Leu	мет	Pro	375	ınr	ASTI	Pro	Pro	380	піѕ	ınr	ser	ASTI
15	Cys 385	Tyr	Asn	Asn	Ser	11e 390	Tyr	Lys	Glu	Gly	Arg 395	Trp	Val	Ala	Asn	Thr 400
20	Asp	Ser	Ser	Gln	Cys 405	He	Asp	Phe	Ser	Asn 410	Tyr	Lys	Glu	Leu	Ala 415	lle
25	Asp	Asp	Asp	Va I 420	Glu	Phe	Trp	lle	Pro 425	Thr	lle	Gly	Asn	Thr 430	Thr	Tyr
30	His	Asp	Ser 435	Trp	Lys	Asp	Ala	Ser 440	Gly	Trp	Ser	Phe	lle 445	Ala	GIn	Gin
35	Lys	Ser 450	Asn	Leu	He	Thr	Thr 455	Met	Glu	Asn	Thr	Lys 460	Phe	Gly	Gly	Val
40		430					400					400				
45	Gly 465	Thr	Ser	Leu	Ser	Asp 470	lle	Thr	Ser	Met	A1 a 475	Glu	Gly	Glu	Leu	Ala 480
50	Ala	Lys	Leu	Thr	Ser 485	Phe	Met	Phe	Gly	His 490	Val					
55																

Claims

10

20

30

40

45

50

55

- 1. A nonhuman animal carrying a gene encoding a soluble form of a membrane protein.
- 5 2. The nonhuman animal of claim 1, which is a transgenic animal into which a gene encoding a soluble protein has been introduced exogenously.
 - 3. The nonhuman animal of claim 2, which is a progeny of the transgenic animal into which a gene encoding a soluble protein has been introduced exogenously.
 - 4. The nonhuman animal of any one of claims 1 to 3, wherein the membrane protein is derived from a virus.
 - 5. The nonhuman animal of claim 4, wherein the virus is a baculovirus.
- 15 **6.** The nonhuman animal of claim 5, wherein the membrane protein is gp64.
 - 7. The nonhuman animal of claim 6, wherein the soluble protein is gp64 that lacks a transmembrane region.
 - 8. The nonhuman animal of claim 6, wherein the soluble protein comprises an extracellular region of gp64.
 - 9. The nonhuman animal of any one of claims 1 to 8, wherein the nonhuman animal is a mouse.
 - 10. The nonhuman animal of any one of claims 6 to 9, wherein the male is fertile.
- 25 **11.** A method for producing an antibody, which comprises the steps of:

immunizing the nonhuman animal of any one of claims 1 to 10 with an immunogen comprising a target antigen; and

obtaining an antibody against the target antigen or a gene encoding such an antibody.

12. The method of claim 11 for producing an antibody, wherein the immunogen is a viral particle or a portion thereof.

- 13. The method of claim 12 for producing an antibody, wherein the virus is a baculovirus.
- 14. The method of any one of claims 11 to 13 for producing an antibody, wherein the target antigen is a membrane protein.
 - 15. A system for producing an antibody, which comprises the nonhuman animal of any one of claims 1 to 10.

			10	6	4F1	2	0			30			4	0			50			6
p64	GAAT	TCC	ACC	ATC	GTA	AGCG	CT	ATT	GTT	PT .	ATAT	rgre	CT.	L Γ ΤΊ\	GGC	GGCG	.i	GGC	GCA	TTC
P • ·	Gaat N	S	T	M	V	S	A	I	V '	L	Y	V	L	L	A	A	7	A	H	- :
			70			80	,			0			10	n		1	10			12
****					••••••	80	••••••			Ĩ			Ĭ	••••••••		······	<u> </u>			Ì
p64	TGCC	TTT	'GCG	GCG	GAG	CACT H	GC.	AACG	CGC	A F	LATG	AAG.	ACG	GGT	CCG	TAC	ΑА	GAT:	[AA]	W
	A	£	A	A	£		C	14	A	Q	m	V	ľ	G	F	1	r			E
			130)		14	0		1	50			16	0		1	70			1
n64	CTTG	GAC	l ATT	ACC	CCG	l	AG	CAAS	, CGC	.L	2022	A A G	l	CTV	CCA		.L	· C b T		
PUT	L	D	I	T	P	P	K	E	T	Ĺ.	Q	K	D	V	E	I	.n. \	' I	V	GG
			190			20														24
		~~~	<u>l</u> .	•••••	• • • • • • • • •	L				<b>1</b> .			. <b></b> .				l	*******		
p64	GACG					AACG N														
	•	_	250																	
						260				. 1										
p64	CAAC	eèco	3GC	TCG	CTG	SATC	CC	AACA	CAC	G C	GTC	GAA	GAA	ACC	YTA:	AAA	AC	GCT	GAA	TG
	N	G				D														
	<b></b>		310			320	<b>)</b> 		3.	10			340	) <i></i>						36
p64	GGGC	AAA	GAG	GAT'	rtgo	ATT	TGT	rgga	GCA:	r C	AGG(	CAGC	CAG	TGC	GAG	GTGG	; G(	CGAA	GAG	CI
	G	K		D	L	L	M	W	s :	I	R	Q	Q	С	E	٧	G	E		
			370			380	)		39				400			41	O			42
p64	GATC		CGT	TGG	GGCA	GTG	ACA	GCG.	<b>ACG</b>	C:			:GC	GAC						
	I	D			G	S		S :										R		
			430			440			45	0			460			47	0			48
p64	GTGG																			
	W	ν	K	G	K	E	L	V I	K F	t	Q	N	N	N	H	F	A	H	H	T
I			490			500	)		51	0			520	l		53	0			54
p64	GTGC	AAC	l \AA	TCG'	rggc	GAT	GCG	GCA	TTTC		ACT	rcga	l LAA	ATG'	TAC	AGCA	G	CTC	GAG	TC
704						R														
1			550			560			57	0		9	580			590	ı		6	ŌΟ
p64	CCAGO	ACC	L	ACG					1		ملدشتان	TCC	AC	درسر	AGG	GC A	ACC	200	4 OT	Ţ
דייק	Q	D	D	T	D	E	c	δ ,	Y		ī	L	D	A	E	G	N	P	I	N
			610			620			63				640			650				60
	0000	200		C	A COMO	1	mmo											7777	200	<u>Ļ</u>
p64	CGTG.					V														
	•	•	670		-	680			69						-	711		16		720
	TACG		1		~~~	1			1				- 1			Ī	_			1
p64	TACG	TTC	ACC	ACG	_GC(	AAA	TA	LAAG	CTGC	: G'	rgtC	TGC	TYC	ביוייוי ב	LAAC	: D-TP-C	ΔС	AAA	LTAP	מו

FIG. 1-a

			73	0		74	0			750	)		76	0		77	0			780
	cccc					CCCC		CAC	m/m	<u></u>	CATT	CAC	7 7 7	GAT	מיד מי	 ጥልጥር	ÞΤ	الماليات	TO T	
p64	P	GAG E	5	V	JACA T	R	E	H	C	L	I	D	N	D	I	Y	D	L	S	K
			79 1			80					)			0		83				840
p64	AAAC	4CG	TGG	AAC	TGC	AAGT	TT	'AAC	AGA'	rg	CATT	AAA'	CGC	AAA	GTC	GAGC	: AC	CGA	GTC	AA
דטק	N	T			C	K		N	R	С	I				V	E	H	R		
			- 1	0		86				- 1			88	<b></b>		89				900
p64	GAAG	CGG	CCC	CC	CACI	TGGC	GC	CAC	AAC	GT	TAG	<i>r</i> ecc	AAG	TAC	CACA	GAGG	GA C	GAC	AC'	rgc N
	K	R			T	W		Ħ				A			T			D	1	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		91	•		92				930			94	-		95	ĺ			960
p64	CACC			GAC	CTG	ATGC	AT	'ATT	CAA	GA.	GGAG	CTG	ATG	TAC	CGAA	AAC(	3 AI	MTTG	CT(	GAA
	Т	K	G		L	M									E					1020
			97	1		1	0				)					10				
n64	AATG	AAC	AT	r GA	GCT	ATGC	r.A	rGCG	CAC	ÃΤ̈́	CAAC	AAG	CTA	AAC	TAA	ATG	TC	CAC	GA	CT
p64		N	I	E	L	M	H	A	H	1	N	K	L	N	N	M	L	H	D	L
			10	30		104	0		1	105	0		10	60		10	70			1080
261	GATA	GTC	TC	GT	GGCC	AAGG	TY	GAC	GAG	CG	TTT	GAT'	rgg(	: AA	TCTC	CATG	A A	CAA	CTC	TGT
p64				V							L									v
			109	0		110	0		1	1,10			112	0		11,3	0			11,40
	TTCTI	~~~~	<u></u>	The street	mmcn	1							ATC	CCG	TGC	CCA	TA	CCG	CCC	GC.
p64	S	S	T	F	L	S	D	D	T	F	L	L	M	P	C	T	N	P	P	A
			115			1160														1200
			L							Ĺ,	CTAC									
p64	ACACA							211/2	· ·		CIMC	بويتين	300	333	-GI	1.000	10			
	H	T	S	N	C	Y	N													
			12,1	0		1220	0		12	2,30			1240	)		125	0			1260 
C.A	GGACT	CGT	CG	CAA	rgc z	TAG	AT"	ידיי	GCA	A	CTAC	AAG	GAA	CTA	GCA	ATTG	AC	GAC	GAC	GT
p64	D			Q	C	I	D	F	S	N	Y	K	E	L	A	I	D	D	D	V
			127	0		128	0		1	290	)		130	0		13	0			1320
p64	CGAGI	TT.	rgg w	ATC	CCG	ACCA T	TO	GGC.	RACA N	T.	GACC T	TAT	H	DAG	AGI S	M	K K	D	BC.	S
	5	F																		1380
			133	U		134 1	U		1	35(	)		136	U		13	/0			1360
p64	CGGCT																			
	G	W	S	F	I	A													$\mathbf{T}$	K
			139	0		140	0		1	410	)		142	0		143	30			1440
-61	GTTTG	GCC	GC	GTC	GGC	ACCA	GT	CTG	AGCC	iA	CATC	ACT	TCC	ATG	GCT	GAAG	GC	GAA	TT	GC
p64	F	G	G	V	Ğ.	T	s	L	S	D	I	T	S	M	A	E	G	E	L	A
ļ			<u>I</u> .		<b>S</b>	146				<del>. Į</del>			<u></u>			<u></u>	···; <u>··</u>			
p64	CGCTA	AA:	LLC	ACT	TCG:	TTCA	TG	TIT	GGTC	:A	TGTA	TAA	TGA	GAA	TIC	(2E)	i IU	NU S	<del>)</del> )	
	A	V.	L	T	_>_	F	m	r	G	n				<u> </u>	E	(SE	טו ו	NU .	10)	

FIG. 1-b





FIG. 2



sgp64 TgM: SOLUBLE FORM gp64 TRANSGENIC MOUSE non-TgM: NON-TRANSGENIC MOUSE

FIG. 3

## INTERNATIONAL SEARCH REPORT

International application No.

			PCT/JP2	005/006298				
	ATION OF SUBJECT MATTER A01K67/027, C07K16/18, C12N15	5/09						
According to Inte	ernational Patent Classification (IPC) or to both national	l classification and IPC						
B. FIELDS SE.	ARCHED							
Minimum documentation searched (classification system followed by classification symbols)  Int.Cl ⁷ A01K67/027, C07K16/18, C12N15/09								
	earched other than minimum documentation to the exter							
BIOTECH	ase consulted during the international search (name of d HNOLOGY ABSTRACT(DIALOG), BIOSI B(JOIS), SwissProt/PIR/GeneSeq,	S(DIALOG), ME	DLINE (STN)	, WPI(DIALOG),				
C. DOCUMEN	TS CONSIDERED TO BE RELEVANT							
Category*	Citation of document, with indication, where app	propriate, of the relevant	t passages	Relevant to claim No.				
X/A	TAMURA Y., et al., CD14 trans expressing membrane and solub comparisons of levels of cyto lethalities in response to li between transgenic and non-trInt.Immunol., (1999), Vol.11,	ole forms: kines and popolysacchar ansgenic mice	.,	1-3,9-10/ 4-8,11-15				
X/A	WATANABE, C. et al., Enhanced immune responses in transgenic mice expressing a truncated form of the lymphocyte semaphoring CD100, J.Immunol., (2001), Vol.167, No.8, p.4321-8.							
Y	LU, W., et al., Characterizat soluble form of the abculovir envelope protein Gp64, Protei (2002), Vol.24, No.2, pages 1	1-15						
× Further do	cuments are listed in the continuation of Box C.	See patent famil	y annex.					
"A" document de to be of parti  "E" earlier applie filing date  "L" document we cited to esta special rease  "O" document re  "P" document pe the priority of		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  "&" document member of the same patent family						
23 June	l completion of the international search e, 2005 (23.06.05)	Date of mailing of the international search report 12 July, 2005 (12.07.05)						
Name and mailin Japanes	gaddress of the ISA/ se Patent Office	Authorized officer						
Faccimile No		Telephone No						

Form PCT/ISA/210 (second sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2005/006298

Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT  Category*  Citation of document, with indication, where appropriate, of the relevant passages  Relevant to clai  Y HEFFERON, K.L., et al., Host cell receptor binding by baculovirus GP64 and kinetics of virion entry, Virology (1999), Vol.258, No.2, p.455-68  Y Toshihiko OTOMO et al., "Gp64 Hatsugen/CCR2 Knockout Mouse Narabini CCR2 Hatsugen Baculovirus o Mochiita Kinoteki Kotai no Sakusei", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu, (2003), Vol.26, page 660  Y Norio KAMATA et al., "gp64 Hatsugen Mouse no Sakushutsu Narabini Hatsugagata Baculovirus ni Taisuru Tolerance Yudo", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu (2003), Vol.26, page659  Y WO 2003/104453 Al (Chugai Pharmaceutical Co., Ltd.), 18 December, 2003 (18.12.03), Full text & AU 2003242024 Al & EP 1514928 Al			PCT/JP2	005/006298
Y HEFFERON, K.L., et al., Host cell receptor binding by baculovirus GP64 and kinetics of virion entry, Virology (1999), Vol.258, No.2, p.455-68  Y Toshihiko OTOMO et al., "Gp64 Hatsugen/CCR2 Knockout Mouse Narabini COR2 Hatsugen Baculovirus o Mochiita Kinoteki Kotai no Sakusei", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu, (2003), Vol.26, page 660  Y Norio KAMATA et al., "gp64 Hatsugen Mouse no Sakushutsu Narabini Hatsugagata Baculovirus ni Taisuru Tolerance Yudo", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu (2003), Vol.26, page659  Y WO 2003/104453 Al (Chugai Pharmaceutical Co., Ltd.), 18 December, 2003 (18.12.03), Full text	C (Continuation	). DOCUMENTS CONSIDERED TO BE RELEVANT		
binding by baculovirus GP64 and kinetics of virion entry, Virology (1999), Vol.258, No.2, p.455-68  Y Toshihiko OTOMO et al., "Gp64 Hatsugen/CCR2 I-15 Knockout Mouse Narabini COR2 Hatsugen Baculovirus o Mochiita Kinoteki Kotai no Sakusei", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu, (2003), Vol.26, page 660  Y Norio KAMATA et al., "gp64 Hatsugen Mouse no Sakushutsu Narabini Hatsugagata Baculovirus ni Taisuru Tolerance Yudo", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu (2003), Vol.26, page659  Y WO 2003/104453 Al (Chugai Pharmaceutical Co., Ltd.), 18 December, 2003 (18.12.03), Full text	Category*	Citation of document, with indication, where appropriate, of the releva	nt passages	Relevant to claim No.
Knockout Mouse Narabini COR2 Hatsugen Baculovirus o Mochiita Kinoteki Kotai no Sakusei", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu, (2003), Vol.26, page 660  Y Norio KAMATA et al., "gp64 Hatsugen Mouse no Sakushutsu Narabini Hatsugagata Baculovirus ni Taisuru Tolerance Yudo", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu (2003), Vol.26, page659  Y WO 2003/104453 Al (Chugai Pharmaceutical Co., Ltd.), 18 December, 2003 (18.12.03), Full text	Y	binding by baculovirus GP64 and kinetics virion entry, Virology (1999), Vol.258, N	of	1-15
Sakushutsu Narabini Hatsugagata Baculovirus ni Taisuru Tolerance Yudo", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshishu (2003), Vol.26, page659  Y WO 2003/104453 Al (Chugai Pharmaceutical 1-15 Co., Ltd.), 18 December, 2003 (18.12.03), Full text	Y	Knockout Mouse Narabini COR2 Hatsugen Baculovirus o Mochiita Kinoteki Kotai no Sakusei", Nihon Bunshi Seibutsu Gakkai Ne	nkai	1-15
Co., Ltd.), 18 December, 2003 (18.12.03), Full text	Y	Sakushutsu Narabini Hatsugagata Baculovir ni Taisuru Tolerance Yudo", Nihon Bunshi Seibutsu Gakkai Nenkai Program Koen Yoshi	us	1-15
	Y	Co., Ltd.), 18 December, 2003 (18.12.03), Full text		1-15

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2005/006298

	FC1/0F2003/000298
Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
1. Claims	al search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:  Nos.:  e they relate to subject matter not required to be searched by this Authority, namely:
	Nos.: e they relate to parts of the international application that do not comply with the prescribed requirements to such an that no meaningful international search can be carried out, specifically:
3. Claims because	Nos.: e they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
The mate a gene end However a membran case (se Vol.167, a contri document Furtherm  1. As all relains. 2. X As all se any add 3. As only	al Searching Authority found multiple inventions in this international application, as follows: there common to claims 1 to 15 resides in a nonhuman animal carrying incoding a soluble protein of a membrane protein.  The protein was known in public on the priority date of the present set. Int.Immunol (1999), Vol.11, No.3, p.333-9, J.Immunol (2001), No.8, p.4321-8, etc.). Thus, this technical feature does not make bution over prior art, considering the disclosures in the above s, and, therefore cannot be considered as a special technical feature. Once, there is no the same or corresponding special technical feature.  Therefore described without effort justifying an additional search report covers all searchable described earchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of the fittional fee.  The special technical search report covers all searchable described earchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of the fittional fee.  The special search fees were timely paid by the applicant, this international search report covers one claims for which fees were paid, specifically claims Nos.:
4.  No req	uired additional search fees were timely paid by the applicant. Consequently, this international search report is ed to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Pro	The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)

#### REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

#### Patent documents cited in the description

- WO 03104453 A [0004]
- WO 9846777 A [0033] [0035]
- JP 9032010 A [0036]
- WO 9312227 A [0047]
- WO 9203918 A [0047]
- WO 9402602 A [0047]

- WO 9425585 A [0047]
- WO 9634096 A [0047]
- WO 9633735 A [0047]
- EP 239400 A [0050]
- WO 9602576 A [0050]

#### Non-patent literature cited in the description

- Biotechnology, 1995, vol. 13, 1079-84 [0004]
- Journal of Immunological Methods, 2000, vol. 234, 123-135 [0004]
- Journal of Virology, 1996, vol. 70 (7), 4607-4616
   [0004]
- Journal of Virology, 1995, vol. 69 (4), 2583-2595
   [0004]
- Gene, 1991, vol. 108, 193-200 [0006]
- Proc. Natl. Acad. Sci. USA, 1980, vol. 77, 7380-7384
   [0022]
- LOISEL, T.P. et al. Nature Biotech., 1997, vol. 15, 1300-1304 [0033] [0035]
- LUCKOW V.A.; SUMMERS M.D. Virol., 1988, vol. 167, 56 [0034]
- D. STREHLOW et al. Proc. Natl. Acad. Sci. USA., 2000, vol. 97, 4209-4214 [0035]
- ALBRECHTSEN et al. J. Virological Methods, 1990, vol. 28, 245-256 [0036]
- HEWISH et al. J. Virological Methods, 1983, vol. 7, 223-228 [0036]
- HJORTH; MERENO-LOPEZ. J. Virological Methods, 1982, vol. 5, 151-158 [0036]

- CROOKS et al. J. Chrom., 1990, vol. 502, 59-68 [0036]
- MENTO S.J. Williamsburg Bioprocessing Conference. Viagene, Inc, 1994 [0036]
- NAJAYOU et al. J. Virological Methods, 1991, vol. 32, 67-77 [0036]
- DIACO et al. J. Gen. Virol., 1986, vol. 67, 345-351
   [0036]
- FOWLER. J. Virological Methods, 1986, vol. 11, 59-74 [0036]
- HARUNA et al. Virology, 1961, vol. 13, 264-267
   [0036]
- GALFRE, G.; MILSTEIN, C. Methods Enzymol., 1981, vol. 73, 3-46 [0042]
- BORREBAECK, C.A.K.; LARRICK, J.W. Therapeutic Monoclonal Antibodies. UK, Macmillan Publishers Ltd, 1990 [0045]
- HUSTON, J.S. Proc. Natl. Acad. Sci. U.S.A., 1988, vol. 85, 5879-5883 [0046]
- SATO, K. et al. Cancer Res., 1993, vol. 53, 851-856 [0050]
- Modern Techniques in Gene Targeting. Yodosha, 2000, 190-207 [0059]